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ABSTRACT OF DISSERTATION

MOLECULAR MECHANISMS OF NEUROPILIN-LIGAND BINDING
Neuropilin (Nrp) is an essential cell surface receptor with dual functionality in the
cardiovascular and nervous systems. The first identified Nrp-ligand family was the
Semaphorin-3 (Sema3) family of axon repulsion molecules. Subsequently, Nrp
was found to serve as a receptor for the vascular endothelial growth factor (VEGF)
family of pro-angiogenic cytokines. In addition to its physiological role, VEGF
signaling via Nrp directly contributes to cancer stemness, growth, and metastasis.
Thus, the Nrp/VEGF signaling axis is a promising anti-cancer therapeutic target.
Interestingly, it has recently been shown that Sema3 and VEGF are functionally
opposed to one another, with Sema3 possessing potent endogenous antiangiogenic activity and VEGF serving as an attractive cue for neuronal axons. We
hypothesized that direct competition for an overlapping binding site within the Nrp
extracellular domain may explain the observed functional competition between
VEGF and Sema3. To test this hypothesis we have separately investigated the
mechanisms of VEGF and Sema3 binding to Nrp. Utilizing structural biology
coupled with biophysics and biochemistry we have identified both distinct and
common mechanisms that facilitate the interaction between Nrp and these two
ligand families. Specifically, we have identified an Nrp binding pocket to which
these ligands competitively bind. The Sema3 family uniquely requires proteolytic
activation in order to engage this overlapping binding site. These findings provide
critical mechanistic insight into VEGF and Sema3 mediated physiology.
Additionally, these data have informed the development of small molecules,
peptides, and soluble receptor fragments that function as potent and selective
inhibitors of VEGF/Nrp binding with exciting therapeutic potential for treating
cancer.
Keywords: Neuropilin (Nrp), Vascular Endothelial Growth Factor (VEGF),
Semaphorin-3 (Sema3), angiogenesis, axon guidance
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CHAPTER 1: BACKGROUND AND INTRODUCTION
Nrp Architecture
Neuropilin (Nrp) was first identified in the optic tectum of Xenopus and
referred to as A5-antigen (Takagi et al., 1991; Takagi et al., 1987). There are two
conserved Nrp family members in vertebrates, Nrp1 and Nrp2, which share the
same overall domain structure and are 44% identical at the amino acid level (Chen
et al., 1997; Kolodkin et al., 1997). Nrp family members are type I transmembrane
proteins

that

possess

an

N-terminal signal

peptide,

two

Ca2+-binding

C1r/C1s/Uegf/Bmp1 (CUB) domains (a1a2) (Gaboriaud et al., 2011), two
coagulation factor V/VIII-like discoidin domains (b1b2) (Fuentes-Prior et al., 2002;
Kiedzierska et al., 2007), a Meprin/A5-antigen/ptp-Mu (MAM) domain (c), a single
transmembrane helix, and a short intracellular domain.

The N-terminal four

extracellular domains are necessary and sufficient for ligand binding. The a1
domain has been shown to interact with the sema domain of Sema3 ligands (Gu
et al., 2002). The b1 domain contains a specific C-terminal arginine binding pocket
and is essential for binding to the C-terminal domain of both vascular endothelial
growth factor (VEGF) and Semaphorin-3 (Sema3) ligands (Parker et al., 2010;
Parker et al., 2012c; Starzec et al., 2007; Teesalu et al., 2009; Vander Kooi et al.,
2007; von Wronski et al., 2006). Additionally, the b1 and b2 domains physically
interact to form an extended patch of basic residues that is involved in binding
heparin, a highly sulfated member of the glycosaminoglycan (GAG) family of
carbohydrates (Vander Kooi et al., 2007). The c domain is dispensable for ligand
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binding but essential for ligand-dependent signaling (Nakamura et al., 1998). The
transmembrane helix possesses a conserved GXXXG repeat and shows strong
inherent dimerization potential (Roth et al., 2008). The intracellular domain of Nrp
interacts with PSD-95/Dlg/ZO-1 (PDZ)-domain proteins, such as GAIP Interacting
Protein, C-terminus (GIPC), via its C-terminal residues (Cai and Reed, 1999).
Deletion of the Nrp1 intracellular domain does not result in embryonic lethality, as
seen with the whole gene, but instead causes defects in vascular patterning
(Fantin et al., 2011).
There are alternative splice forms of Nrp1 and Nrp2 that have been shown
to have functional implications. The most commonly identified alternative splice
forms of both Nrp1 and Nrp2 result from intron inclusion in the region between b2
and c domains (Gagnon et al., 2000; Rossignol et al., 2000). The included intron
contains a stop-codon resulting in production of secreted soluble proteins that
preserve ligand binding and thus function as endogenous pathway inhibitors.
Alternative splicing of Nrp2 also produces two species with divergent C-terminal
intracellular domains. While multiple splice forms of both Nrp receptors exist, the
functional significance of these divergent sequences is largely unknown.

In

addition to splice variants, there are a number of post-translational modifications
that alter Nrp function. Nrp1 and Nrp2 can be modified by both N- and O-linked
glycans. Nrp1 has been shown to be modified by heparan- or chondroitin-sulfate
which results in increased ligand binding (Shintani et al., 2006).

Thus, this

modification may poise or pre-activate Nrp for signaling. In contrast, Nrp2 is
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modified by polysialic acid resulting in enhanced dendritic cell migration (Curreli et
al., 2007; Rey-Gallardo et al., 2010).
Nrp Function in Sema3 Dependent Axon Guidance
Nrp was initially identified and functionally characterized as a receptor for
the Sema3 family ligands in neurons. Neurons function in cooperative neural
networks connected by dendrites and axons. The number and type of axonal
connections are tightly regulated by guidance cues. One family of essential axon
guidance molecules are the Semaphorins.

There are seven Sema3 family

members (Sema3A-G) that are secreted, diffuse through tissues, and provide
guidance cues (Kolodkin et al., 1993). Indeed, axon guidance cues mediated by
Sema3 family members are essential during development for correct neuronal
patterning in dorsal root ganglia, facial, vagal, olfactory-sensory, cortical,
hippocampal, and cerebellar nerves, along with others (Koncina et al., 2007).
Sema3 family members bind Nrp receptors on the cell surface (He and
Tessier-Lavigne, 1997; Kolodkin et al., 1997) (Figure 1.1). The N-terminal a1
domain of Nrp1 and Nrp2 selectively binds the sema domain of different Sema3
family members (Chen et al., 1998; Koppel et al., 1997; Merte et al., 2010).
Notably, Sema3A specifically signals via Nrp1 (He and Tessier-Lavigne, 1997;
Kolodkin et al., 1997) and Sema3F via Nrp2 (Giger et al., 1998). The Nrp b1
domain allows high-affinity non-selective binding to the Sema3 C-terminal domain
(Giger et al., 1998; Nakamura et al., 1998; Parker et al., 2010). Following Sema3
binding by Nrp, Plexin family signaling receptors (PlexinA1-4) are then engaged
and activated to directly guide axonal growth (Puschel, 2002; Takahashi et al.,
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1999). Nrp functions by coupling specific high-affinity Sema3 binding to Plexindependent regulation of cytoskeleton dynamics in the axonal growth cone
(Takahashi et al., 1999).

Collapse of the actin cytoskeleton results in axon

repulsion and this appears to represent the most common modality for Nrpdependent Sema3 function. However, Sema3 signaling can also be attractive
rather than repulsive, such as when cGMP levels are high (Song et al., 1998).
Sema3 functionality also drives the pathological repulsion of axons following spinal
cord injury where fibroblasts, which invade the glial scar, secrete members of the
Sema3 family and prevent regrowth of axons. Thus, inhibition of the Sema3/Nrp
signaling axis represents a promising therapeutic modality for functional recovery
following spinal cord injury (De Winter et al., 2002; Fawcett, 2006; Pasterkamp et
al., 1999).
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Figure 1.1: Nrp function is essential for Sema3 dependent axon guidance.
Nrps specifically bind to Sema3 family members through a bivalent binding
mechanism allowing both specific and high-affinity binding. Engagement and
activation of Plexin family receptors activates signaling in both physiological axon
guidance and pathological spinal cord injury. Structures of proteins or homologues
with known structures were utilized including: Semaphorin N-terminus: PDB=1OLZ
(Love et al., 2003); Nrp N-terminal domains: PDB=2QQK (Appleton et al., 2007);
Plexin extracellular domain N-terminus: PDB=3OKT (Janssen et al., 2010); Plexin
intracellular domain: PDB=3IG3 (He et al., 2009).
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Nrp Function in VEGF Dependent Angiogenesis
Angiogenesis is the process by which new vasculature is formed by
branching or splitting from existing vasculature. Physiological angiogenesis is
critical during development, for homeostatic maintenance of vasculature, and
wound healing. Among the most potent pro-angiogenic cytokine families is the
VEGF family. VEGF-A was the first identified family member (Ferrara and Henzel,
1989; Senger et al., 1983), which also includes VEGF-B, -C, D, and placental
growth factor (PlGF) (Ferrara et al., 2003). The different family members have
both unique and partially overlapping functions. VEGF-A, -B and PlGF regulate
hemangiogenesis by Nrp1 (Migdal et al., 1998; Soker et al., 1998; Zhang et al.,
2009). VEGF-C and -D regulate lymphangiogenesis by Nrp2 (Mattila et al., 2002).
Also, VEGF-B has recently been shown to control lipid transport in endothelial cells
by Nrp1 (Hagberg et al., 2010). To add to the complexity, VEGF-A, -B, and PlGF
all have numerous alternative splice forms with varying physical and functional
properties (Leung et al., 1989; Nowak et al., 2008) whereas VEGF-C and -D
require proteolytic processing from a pre-protein for activation (Joukov et al.,
1997). Nrp1 was initially identified as a VEGF-A165 splice-form specific receptor
(Soker et al., 1998). More recent work has demonstrated that Nrp1 can also bind
other VEGF-A isoforms (Pan et al., 2007b; von Wronski et al., 2007) yet uniquely
and specifically physically engages VEGF-A165 (Parker et al., 2012c).
VEGF-A is secreted by an initiating tissue, typically in response to hypoxia,
and diffuses to nearby vessels where it binds to two families of essential
endothelial cell-surface receptors: VEGF-receptor (VEGFR) tyrosine kinases
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(Ferrara et al., 2003) and Nrps (Migdal et al., 1998; Soker et al., 1998) (Figure 1.2).
VEGF-A binding causes initiation of the angiogenic cascade, which involves
activation of endothelial cells, basement membrane remodeling, proliferation of
endothelial cells, and directional guidance leading to the growth of new vasculature
towards the initiating tissue.

Importantly, angiogenic signaling is only

accomplished through the coordinated activity of VEGF, VEGFR, and Nrp
(Klagsbrun et al., 2002). While VEGF binding to VEGFR weakly activates its
intracellular kinase activity, Nrp is required for strong and sustained kinase
activation leading to initiation of the pro-angiogenic cascade (Becker et al., 2005;
Soker et al., 2002). Nrp1 null mice die in utero due to defective vasculature
formation, thus emphasizing the critical role of Nrp in angiogenesis (Kitsukawa et
al., 1997). Importantly, abnormalities associated with loss of Nrp1 are caused by
defective endothelial cell migration rather than proliferation (Jones et al., 2008).
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Figure 1.2: Nrp function is essential for VEGF dependent angiogenesis.
Nrps specifically bind to the C-terminal basic domain of VEGF family members.
Cooperative binding of VEGF by VEGFR and Nrp activates the angiogenic
cascade necessary for developmental and homeostatic angiogenesis and also
pathological signaling associated with tumorigenesis and other types of aberrant
signaling. Structures of proteins with known structures were utilized including:
VEGF-A cystine knot domain: PDB=2VPF (Muller et al., 1997); VEGF-A basic
domain: PDB=4DEQ (Parker et al., 2012c); Nrp N-terminal domains: PDB=2QQK
(Appleton et al., 2007); VEGFR2 Ig-like domain 2-3: PDB=2X1X (Leppanen et al.,
2010); VEGFR2 Ig-like domain 7: PDB=3KVQ (Yang et al., 2010); VEGFR2
intracellular domain: PDB=1VR2 (McTigue et al., 1999).
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Ligand Mediated Cross-Talk
Intriguingly, it has been noted that blood vessels and nerves utilize similar
signals and principles for guidance (Adams and Eichmann, 2010; Arese et al.,
2011; Carmeliet, 2003). Indeed, recent studies have identified an embryonic stem
cell-derived population of cells that differentiate towards either vascular or
neuronal cell-type depending on the microenvironment (Gualandris et al., 2009).
Nrp receptors are expressed in nerves and endothelial cells, and both cell types
are responsive to secreted ligands of the Sema3 and VEGF families (Erskine et
al., 2011; Miao et al., 1999; Schwarz et al., 2004). Not only are both cell types
responsive to each family of ligands, but the different ligands can compete for Nrp
binding (Figure 1.3).
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Figure 1.3: Cross-talk between Nrp ligands allows coordinated regulation of
neuronal and vascular tissues.
Both neurons and endothelial cells express Nrp which can respond to either
Sema3 or VEGF family guidance cues. Regulation of competitive Nrp binding
between different ligands allows for an additional level of dominant control of Nrp
function.
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Nrp in Tumor Angiogenesis
Nrp function is important not only for physiological angiogenesis but also in
VEGF-dependent pathological hyper-vascularization in tumor angiogenesis (Bagri
et al., 2009). It has long been known that the extent of tumor vascularization is
correlated to tumor size (Algire and H.W., 1945) and that diffusible factors are able
to induce neovascularization in solid tumors (Greenblatt and Shubi, 1968). Antiangiogenesis therapies (Folkman, 1971) are now used against a range of solid
tumors. Avastin, a monoclonal antibody targeting VEGF-A, has been among the
most successful angiogenesis inhibitors (Ferrara et al., 2005). While providing
significant benefit it has been noted that when patients relapse, those that received
anti-angiogenesis treatment often have more aggressive and metastatic tumors
(Ebos et al., 2009; Paez-Ribes et al., 2009). Aberrant Nrp expression and function
promotes tumorigenesis and metastasis in vivo in a variety of solid tumors
(Bielenberg et al., 2006; Ellis, 2006; Guttmann-Raviv et al., 2006; Klagsbrun et al.,
2002). Surprisingly, in addition to expression in tumor vasculature, direct Nrp
overexpression in malignant cells has been widely reported.
Nrp Tumor Cell Expression and Autocrine Activation
The initial identification of Nrp as a receptor for VEGF noted its expression
in both endothelial and tumor cells (Soker et al., 1998). Since then, aberrant Nrp
expression in a wide variety of malignant cells has been observed (Banerjee et al.,
2000; Kreuter et al., 2006; Miao et al., 2000; Stephenson et al., 2002; Vacca et al.,
2006). The function of Nrp in tumor cells, and its contribution to tumorigenesis, is
the source of considerable interest. Recently, Nrp expression was demonstrated

11

to be critical for autocrine activation of tumor cells, influencing carcinoma survival
(Bachelder et al., 2001), growth (Cao et al., 2012), and migration (Bachelder et al.,
2003; Bagci et al., 2009). Nrp-dependent autocrine activation provides a basis for
understanding why Nrp expression and function directly correlates to both tumor
aggressiveness (Goel et al., 2013) and the metastatic potential of a variety of solid
tumors (Latil et al., 2000; Ochiumi et al., 2006). Further, Nrp function in tumor cells
has been tied to dedifferentiation and stemness (Cao et al., 2008). It has recently
been shown that Nrp1 directly contributes to the self-renewal of cancer stem cells
in skin cancer (Beck et al., 2011). Indeed, Nrp1 deletion blocked the ability of
VEGF to promote cancer stem cell self-renewal. Further, an autocrine activation
pathway involving Nrp1 was shown to contribute to stem-like cell viability and
tumor growth in glioma (Hamerlik et al., 2012). The multi-functional role for Nrp in
tumor initiation and progression has motivated research focusing on developing
novel Nrp inhibitory modalities. Additionally, as the genetic profile of various tumors
is characterized it will be interesting to determine whether there are specific gainof-function mutations within the Nrp gene that further contribute to its tumorigenic
activity.
General Modes of Nrp Action
Nrps are normally expressed in a variety of tissue types including the
previously discussed nerves and vascular tissues along with immune and
hematopoietic cells (Tordjman et al., 2002; Yamada et al., 2003). In addition to
the critical role for Nrp in the Sema3 and VEGF pathways, interactions with a
number of other ligands and receptors have been reported.
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Other ligands

identified include members of the fibroblast growth factor (FGF) family, plateletderived growth factor (PDGF), transforming growth factor β1 (TGF- β1), and
hepatocyte growth factor/scatter factor (HGF/SF) functioning via receptors in the
FGFR, PDGFR, TβRs and c-Met families, respectively (Banerjee et al., 2006; Cao
et al., 2010a; Cao et al., 2010b; Glinka and Prud'homme, 2008; Goel et al., 2013;
Holmes and Zachary, 2008; Hu et al., 2007; Matsushita et al., 2007; West et al.,
2005). In light of the diverse expression profile and functional interactions,
determining the general mechanism(s) of Nrp action is critical to further our
understanding of physiological and pathological functions of Nrp.
Nrp Functions by Physically Organizing the Full Signaling Complex
As a primary function, Nrps promote pathway activation by recruiting ligands
to the cell surface through high-affinity interactions (Figure 1.4, A).

This is

particularly important in Sema3 binding, which is the only diffusible Sema family
and requires Nrp for cell-surface binding (Zhou et al., 2008). Additionally, Nrps
show selective binding to different members within the VEGF and Sema3 families.
The basis for specific Nrp1-VEGF-A interactions in hemangiogenesis has been
described biochemically and structurally (Geretti et al., 2007; Parker et al., 2012b),
and other family members are actively being pursued.
Ligand binding is followed by assembly of the active signaling complex,
where Nrp functions to promote and stabilize the active signaling holoenzyme
(Shraga-Heled et al., 2007; Soker et al., 2002; Takahashi et al., 1999) (Figure 1.4,
B). Assembly of the active signaling complex requires both receptor recruitment
and binding associated conformational changes, providing the physical
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mechanism required for signal transduction. Importantly, Nrp ligands are dimeric,
with conserved intermolecular disulfide bonds.

Thus, the minimum signaling

holocomplex is thought to involve a dimeric ligand bound to two Nrp molecules and
two signaling receptors. Energetically, it appears that highly favorable ligand
binding drives the formation of specific homo- and hetero-typic receptor contacts
that do not occur spontaneously (Brozzo et al., 2012; Fuh et al., 2000). This is
consistent with optimal receptor function, with physical mechanisms strongly
inhibiting spontaneous ligand-independent activation.
Understanding Nrp function in holocomplex assembly requires knowledge
of the structure and interactions of the receptor both before and after ligand
binding.

The a2b1b2 domains of Nrp have been reported to adopt a stably

associated trimeric core with loosely tethered a1 domain (Appleton et al., 2007).
The c/MAM domain, which is dispensable for ligand binding but essential for
ligand-induced signaling (Nakamura et al., 1998), has been reported to form homoand hetero-dimers between Nrp1 and Nrp2 (Chen et al., 1998).

However,

experiments with purified protein have reported that there is no self-association or
dimerization propensity observable for the Nrp ectodomain, leaving the structure
and physical coupling of the MAM domain within Nrp an open question (Appleton
et al., 2007).
GAG binding also plays a critical role in Nrp-dependent signaling. GAGs
are a diverse family of naturally occurring sulfated polysaccharides that orchestrate
numerous processes including the function of endothelial cells in angiogenesis
(Stringer, 2006). GAG binding dramatically enhances Nrp-ligand interactions and
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drives dimerization of Nrp (Fuh et al., 2000; Vander Kooi et al., 2007). Thus, GAG
binding likely plays a dual role by bridging and stabilizing the dimer holocomplex
assembly.
Intriguingly, a number of receptors have been shown to associate with Nrp
in a ligand independent fashion.

A direct and specific interaction has been

demonstrated between Nrp1 and VEGFR1 (Fuh et al., 2000). Nrp and Plexin
family receptors have also been shown to associate in a ligand independent
manner (Takahashi and Strittmatter, 2001). In these cases, rather than having
sequential receptor binding, the pre-associated receptor complex is poised to bind
and signal and only requires conformational changes (Figure 1.4, C).
Nrp Trafficking
Following ligand binding and assembly of the active signaling complex, Nrp
has been demonstrated to have a critical function in receptor trafficking (Figure
1.4, D). Intriguingly, it was shown that Sema3 and VEGF induce Nrp1 endocytosis
via distinct pathways (Salikhova et al., 2008).

Further, Nrp promotes the

partitioning of VEGFR into vesicles that are recycled back to the cell surface,
whereas in the absence of Nrp, VEGFR2 is targeted for degradation instead of
recycling (Ballmer-Hofer et al., 2011). The intracellular GIPC-binding domain of
Nrp was demonstrated to be essential for the observed VEGFR recycling,
suggesting the involvement of a Nrp-associated cytoplasmic protein.
The Nrp Intracellular Domain
The discovery of the Nrp-binding PDZ-protein GIPC provided a mechanism
by which Nrp may directly couple to intracellular adaptors and pathways (Cai and
15

Reed, 1999) (Figure 1.4, E). The critical portion of the Nrp intracellular domain is
the three C-terminal amino acids, conserved in Nrp1 and Nrp2, that constitute a
PDZ-binding motif and allow binding to PDZ-domain proteins. Increasing evidence
implicates the intracellular domain of Nrp in a variety of biological processes. Mice
expressing a mutant Nrp receptor with deleted cytoplasmic domain were
generated (Fantin et al., 2011).

While capable of binding ligand, these Nrp

receptors are decoupled from signal transduction via its PDZ-binding motif and
GIPC and result in vascular abnormalities distinct from those of full Nrp1 knockout.
Angiogenesis was unaffected but vascular patterning was disrupted as evidenced
by frequent crossing of arteries and veins in the retina. A similar approach was
applied in zebrafish, demonstrating that knockdown of Nrp1 does disrupt
angiogenesis and only full length Nrp, not a Nrp1 construct lacking the three Cterminal amino acids, is able to rescue disrupted blood vessel growth (Wang et al.,
2006).

Further, deletion of the PDZ-binding C-terminal amino acids of Nrp1

disrupted stable association of the full angiogenic signaling complex with VEGFR2 (Prahst et al., 2008). There is also growing evidence for Nrp function in the
absence of other recognized receptor families. Specifically, Nrp is capable of
mediating adhesiveness (Murga et al., 2005) and migration (Wang et al., 2003) of
endothelial cells in the absence of VEGFR2, functions that require the C-terminal
PDZ-binding motif of the Nrp intracellular domain.
Interaction with a common intracellular adaptor, such as GIPC, suggests
that Nrp function in physiologically diverse pathways may be due to coupling to
basic cellular signaling pathways. Intriguingly, the integrin subunits α6 and α5 have
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been reported to interact with GIPC via their C-terminus (Tani and Mercurio, 2001),
(El Mourabit et al., 2002).
Nrp Coupling with Integrins
Integrins mediate interactions with the extracellular matrix and as a result
are important for cellular adhesion and migration. Indeed, the biological function
first associated with Nrp1 was its ability to mediate heterophilic cellular adhesion
(Takagi et al., 1995). A variety of studies have now demonstrated that both Nrp1
and Nrp2 physically and functionally associate with integrins (Fukasawa et al.,
2007; Goel et al., 2012; Serini et al., 2003) (Figure 1.4, F).
Exogenous Sema3 was able to inhibit the adhesion of endothelial cells to
the integrin ligands fibronectin and vitronectin, while VEGF enhanced the adhesive
strength of endothelial cells (Serini et al., 2003). Furthermore, a recent study
demonstrated that Nrp1 was necessary for endothelial cell adhesion to fibronectin
(Valdembri et al., 2009). Surprisingly, rescue of fibronectin binding following Nrp1
knockdown was only seen using vectors carrying full-length Nrp but not Nrp
constructs lacking the C-terminal PDZ-binding motif, suggesting coupling between
integrin and PDZ-domain proteins. αvβ3 integrin has been shown to interact with
Nrp1 in a VEGF-dependent fashion and this serves to sequester Nrp1 from the
active VEGF/VEGFR2 signaling complex thereby limiting angiogenesis (Robinson
et al., 2009). The function of integrins in controlling cellular migration led to
investigation of the interplay between Nrp1 and integrin β1, demonstrating that
blockade of either Nrp1 or β1 resulted in reduced invasiveness and adhesion in a
pancreatic cancer cell line (Fukasawa et al., 2007). Recently, an important specific
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role for Nrp2 in integrin-mediated adhesion has also been defined. Nrp2 makes
specific interactions with integrin α6β1 at focal adhesion sites. Depleting Nrp2
expression in breast carcinoma cells inhibited focal adhesion assembly of these
cells and regulated the downstream targets of α6β1 integrin that ultimately
modulate laminin adhesion (Goel et al., 2012). These data demonstrate that Nrp
and integrin receptors function cooperatively to regulate cellular adhesion and
there is considerable interest in understanding the precise nature of the physical
coupling and extent of biological function.
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Figure 1.4: Nrp utilizes common mechanisms to regulate diverse signaling
pathways.
A) Specific high-affinity ligand binding initiates Nrp mediated signaling.

B)

Engagement and organization of an active signaling complex is accomplished
through specific receptor-ligand and co-receptor contacts. C) Ligand-independent
receptor association forms a pre-activated receptor complex poised for signaling.
D) Nrp regulates dynamic trafficking of signaling complexes.

E) Binding of

intracellular PDZ-domain proteins, including GIPC, allow direct coupling between
Nrp ligand binding and signaling functions. F) Direct engagement of integrins
allows Nrp to couple molecular events with cellular cues.
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Scope of Dissertation
As previously discussed, the b1 domain of Nrp is responsible for binding the Cterminal domain of both VEGF and Sema3. Three coagulation-factor loops of the
b1 domain form a conserved binding pocket specific for C-terminal arginine
containing ligands (Lee et al., 2003; Parker et al., 2012c; Vander Kooi et al., 2007).
All VEGF family members possess a C-terminal arginine, which is necessary for
binding to Nrp. In contrast, no Sema3 family members possess a C-terminal
arginine. However, all Sema3 family members contain furin-like protease RXXR
consensus sites in their C-terminal domain (Adams et al., 1997). The interplay of
VEGF and Sema3 is important for diseases associated with angiogenesis.
Aberrant hypo-vascularization was recently demonstrated in the retina where
expression of Sema3A prevents revascularization of ischemic neural tissue (Joyal
et al., 2011). In contrast, aberrant hyper-vascularization is associated with VEGF
upregulation or Sema3 downregulation in pathological angiogenesis of solid
tumors (Neufeld et al., 2005; Sakurai et al., 2012; Vacca et al., 2006).
In order to gain an understanding of the complex physiological interplay
between VEGF and Sema3, this dissertation aimed to understand both the distinct
and overlapping mechanisms utilized by Nrp to bind these two ligand families. In
Chapters 3-4 we describe the molecular basis for Sema3 binding to Nrp, which is
regulated by C-terminal proteolysis (Parker et al., 2010; Parker et al., 2013). In
Chapters 5-6 we investigate the physical mechanisms of Nrp1/VEGF-A and
Nrp2/VEGF-C binding using structural biology and biochemistry (Parker et al.,
2012c). Finally, we merge this knowledge in the concluding Chapters (Chapters 7-
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8) to investigate the use of peptides, soluble receptor fragments, and small
molecules as inhibitors of Nrp-ligand binding that hold significant therapeutic
promise (Parker and Vander Kooi, 2014; Parker et al., 2012b).

Reprinted in full or part with permission from: Function of Members of the
Neuropilin Family as Essential Pleiotropic Cell Surface Receptors. Matthew
W. Parker, Hou-Fu Guo, Xiaobo Li, Andrew D. Linkugel, and Craig W. Vander
Kooi, Biochemistry 2012 51 (47), 9437-9446. Copyright 2012 American Chemical
Society.
Copyright © Matthew W. Parker 2014
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CHAPTER 2: MATERIALS AND METHODS
Protein expression and purification
Human Nrp2-b1b2 (residues 276-595), human Nrp1-b1b2 (274-584), a
fusion of human Nrp1-b1 (274-429) linked to the VEGF-A HBD (115-165) with an
intervening Sal1 restriction site and 3X(GS), human Nrp2-b1 (residues 276-430),
human Nrp2-T319R (residues 276-595 with T319R mutation), human Nrp1T316R, s9Nrp2B (residues 275-547 plus the unique intron-encoded C-terminal
insertion: VGCSWRPL) and the Nrp2-b1b2/VEGF-C fusion were expressed as
hexa-histidine fusion proteins from pET28b in E. coli strain Rosetta Gami-2(DE3)
(Novagen/EMD Millipore, Billerica, MA). Nrp2-T319R and Nrp1-T316R were
generated by megaprimer mutagenesis (Vander Kooi, 2013). To generate the
Nrp2/VEGF-C fusion, the five C-terminal residues of VEGF-C (223-SIIRR-227)
were appended to the C-terminus of Nrp2-b1b2 (276-595) by incorporating the
VEGF-C sequence into the reverse primer during cloning. Likewise, generation of
s9Nrp2B involved primer incorporation of the sequence VGCSWRPL C-terminal to
residues 275-547. All constructs and mutations were sequence verified. Cells
were grown in terrific broth and cold shocked at an OD600 = 1.5. Following induction
with 1 M IPTG, cells were grown overnight at 16°C. Harvested cells were lysed by
sonication and lysozyme treatment and proteins were purified via immobilized
metal ion affinity chromatography (IMAC) (HIS-Select HF Nickel Affinity Gel,
Sigma-Aldrich, St. Louis, MO) and eluted with 300 mM Imidazole, 200 mM NaCl.
Nrp2-b1b2, Nrp2-T319R, and the fusion protein were subsequently subjected to
heparin affinity chromatography (HiTrap Heparin HP, GE Healthcare Life
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Sciences, Pittsburgh, PA). Nrp2-b1 and s9Nrp2B, which were incubated for 48
hours to facilitate production of the disulfide-linked dimer, were further purified by
size exclusion chromatography using a Superdex75 HiLoad 16/60 column (GE
Healthcare Life Sciences) equilibrated and run with 20 mM Tris pH 7.5, 100 mM
NaCl.
Alkaline-phosphatase tagged mouse VEGF-A164 (residues 27-190) (AP-VEGFA164), AP-VEGF-A164 mutants, human AP-VEGF-A165 (residues 27-191), mouse
AP-VEGF-C (residues 108-223), AP-VEGF-C R223E, human AP-Sema3F
(residues 20-779), and the Ig-Basic domain of human Sema3F (residues 605-779)
were expressed in Chinese Hamster Ovary (CHO) cells via large-scale transient
transfection from pAPtag-5 vector (GenHunter, Nashville, TN)(Parker et al., 2010).
The C-terminal Nrp binding region of human Sema3F (residues 605-785 (Gu et
al., 2002)) was produced as a C-terminal or an N-terminal Human Growth
Hormone (Hgh) fusion from the pLexM vector (Aricescu et al., 2006; Leahy et al.,
2000).

Protein was produced from CHO, furin deficient FD11, and furin

overexpressing cells (Gordon et al., 1995). Protein was also produced in COS-7
cells in the absence and presence of Dec-RVKR-CMK and D-poly-Arg-NH2 furin
inhibitors (Calbiochem, San Diego, CA).

Cells were maintained in a-MEM

supplemented with 5% FBS. For protein expression, cells were transferred to
Hybridoma-SFM media (Invitrogen, Carlsbad, CA) when they reached 80%
confluence and transfected with PEI-MAX (Polysciences Inc., Warrington, PA)
using 1mg DNA/mL media and a 3:1 PEI:DNA ratio.

23

Differential scanning fluorimetry (DSF)
Peptides

corresponding

to

processed

(RQVHSIIRR)

and

unprocessed

(RQVHSIIRRSLPA) VEGF-C were produced with an N-terminal tryptophan for
quantitation by UV280 absorbance (LifeTein LLC, Hillsborough, NJ). Peptides were
resuspended and combined with 2 μM of Nrp2-b1b2 and 5x SYPRO Orange
Protein Gel Stain (Life Technologies, Grand Island, NY) in PBS. Nrp2-b1b2 melting
was monitored on a CFX96 Real-Time PCR system (BioRad, Hercules, CA) from
20 to 90°C at a rate of 1°C/50s with fluorescent readings taken every 1°C.
Structure determination
For crystallization, the His-tag was removed from all proteins after IMAC
purification by overnight incubation with thrombin. Purified Nrp2-b1b2-VEGF-C
fusion in 250 mM NaCl, 10 mM Tris pH 7.5, Nrp2-T319R in 100 mM NaCl, 5 mM
Tris pH 7.5, and s9Nrp2B in 100 mM NaCl, 20 mM Tris pH 7.5 were concentrated
to 2.0 mg/mL, 2.1 mg/mL and 3.5 mg/mL, respectively, and crystals were grown
by hanging-drop vapor-diffusion experiments at RT. Crystals of the fusion protein
were obtained in two weeks in 0.1 M MES pH 6.5, 0.5 M Ammonium Sulfate. Nrp2T319R crystals were obtained in five days in 0.1 M HEPES pH 7, 18% (w/v) PEG
12000 and crystals of s9Nrp2B were grown in 10% PEG 1000/10% PEG 8000. The
Nrp-VEGF-A HBD fusion protein was concentrated to 5mg/mL and mixed in a 3:1
ratio of protein to mother liquor containing 1.5M Na/K phosphate pH=6.5. Crystals
formed in 1-2 weeks at 23°C. Crystals were passed through mother liquor
supplemented with 10% glycerol and then flash frozen in liquid nitrogen. Diffraction
data were collected at the SER-CAT 22-ID and 22-BM beamlines of the Advanced
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Photon Source, Argonne National Laboratories. Data were processed using
HKL2000 (Otwinowski and Minor, 1997) (Table 1).
The structure of the Nrp2-b1b2-VEGF-C fusion and Nrp2-T319R were
solved by molecular replacement with wild-type Nrp2-b1b2 (PDB code = 2QQJ)
used as a search model. The b1 domain residues of 2QQJ (residues 276-427)
were used as a search model for the s9Nrp2B molecular replacement solution. An
initial molecular replacement solution for the Nrp-VEGF-A HBD fusion protein was
obtained using PHASER with Nrp1-b1 (PDB=2QQI) as the search model (McCoy
et al., 2007). Clear electron density for the VEGF-A HBD was observed and
manually built.
Following molecular replacement,

iterative

modeling building and

refinement was done using COOT (Emsley et al., 2010) and Refmac5 (Murshudov,
1997) to generate a final refined model (Table 1). To characterize intermolecular
interactions, the structures were analyzed using the PISA interaction server
(http://www.ebi.ac.uk/ msd-srv/prot_int/pistart.html) and Ligplot+ (Laskowski and
Swindells, 2011). Protein geometry was analyzed using MolProbity (Chen et al.,
2010) and Superpose was used to calculate a difference density matrix (DDM) for
the apo-Nrp2-b1b2 and complex structure (Maiti et al., 2004). Graphics were
prepared with Pymol molecular graphics software (www.pymol.org).
The atomic coordinates and structure factors have been deposited in the
Protein Data Bank (PDB), www.pdb.org.
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Affinity pull-down
Nrp2 was coupled to AffiGel (Bio-Rad, Hercules, CA) according to manufacturer’s
recommendation at 5 mg protein/mL resin. N-terminally tagged Sema3F Ig-basic
was expressed in Cos-7 cells with and without furin inhibitors.

200mL of

conditioned media was diluted to 1 mL with Buffer A (20 mM Tris, pH=7.5, 100 mM
NaCl) and incubated with 100 mL of Nrp2 affinity resin for thirty minutes. Resin
was washed three times with Buffer A, and then eluted using 1 M NaCl. Eluted
protein was resolved using SDS-PAGE and visualized by western blot.
Fluorescence Aniosotropy
C-furSema was synthesized with an N-terminal Fluorescein isothiocyanate (FITC)
(Genscript). The peptide was resuspended and buffer exchanged into Buffer A.
1.8 mM FITC C-furSema was combined with increasing concentrations of Nrp2
and Nrp1. Fluorescence anisotropy was measured at 23C using a SpectraMax
M5 (Molecular Devices, Sunnyvale, CA) with excitation at 485 nm, emission at 525
nm, and an emission filter at 515 nm). Anisotropy was calculated from the average
of three independent samples at each point using the experimentally determined
G-factor of 1.113. Dissociation constants (Kd) were calculated by fitting the data
with Kaleida-Graph (Synergy Software, Reading, PA) using a single site model:

where ro is the initial anisotropy and ra is the difference in anisotropy between
bound and free species.
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In vitro plate binding assay
Nrp1 affinity plates were produced by diluting Nrp1-b1b2 to either 50, 25, or 2.5
ng/μl in 50 mM Na2CO3 pH 10.4 and 100 μl was added to 96 well protein highbinding plates (Costar, 9018), incubated for 1 hr at 37 °C, washed 5x 100 μl with
PBS-T (PBS, 0.1% Tween20), and stored at 4 °C. Peptides were synthesized
using solid phase synthesis and purified to >95% purity. The well characterized
Nrp inhibitory peptide ATWLPPR was used as a positive control (Sigma-Genosys,
St. Louis, MO). Two dimeric disulfide linked peptides of the C-terminal region of
Sema3F were synthesized, oxidized to produce the natural intramolecular
disulfide, and purified (Genscript, Piscataway, NJ).
corresponds

to

the

final

46

One peptide, C-Sema,

residues

of

Sema3F

(GLIHQYCQGYWRHVPPSPREAPGAPRSPEPDQKKPRNRRHHPPDT) while the
second peptide, C-furSema, is 40 residues and corresponds to the furin cleaved
species (GLIHQYCQGYWRHVPPSPREA PGAPRSPEPQDQKKPRNRR). Two
peptide libraries, one in which the C-1 residue of the S3F C-terminus
(WDQKKPRNXR) was substituted for all twenty amino acids and another that
corresponded to the last nine residues of all Sema3 family members, were
synthesized and purified by HPLC, with an average purity of 90% (NEO Group,
Cambridge, MA). An N-terminal tryptophan was added to aid in quantitation.
Peptides were resuspended in binding buffer and combined with AP-VEGF-A
at peptide concentrations ranging from 500 μM to 230 nM and a final AP-VEGF-A
activity of 1 μmol of pNPP hydrolyzed/min per μl. The pre-mixed AP-VEGFA/peptide solution was then added to Nrp1 affinity plates and incubated for 1 hr at
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25 °C. Wells were washed with 100 μl of PBS-T three times using an EL404 plate
washer (BioTek, Winooski, VT) and an additional 100 μl of PBS-T was added to
the plate and incubated for 5 min. The wash solution was then removed and 100
μl of 1X alkaline phosphatase substrate was added(Jardin et al., 2008). After 25
minutes the reaction was quenched by adding 100 μl of 0.5N NaOH and the plate
was read at 405 nm on a SpectraMax M5 plate reader (Molecular Devices,
Sunnyvale, CA). Retained AP-VEGF-A binding was plotted against peptide
concentration to generate an inhibition curve that was fit with a four-parameter
sigmoidal dose response curve to determine the half-maximal inhibitory
concentration (IC50). Results are reported for each peptide as the mean IC 50 ±
standard deviation of two independent experiments.
For quantitative binding experiments, the absolute concentration of APVEGF-A164 and AP-VEGF-A120 was determined using the quantitative MMV00
enzyme linked immunosorbent assay (ELISA) (R&D Systems). Binding of APVEGF-A164 and AP-VEGF-A120 to Nrp1 or Nrp2 was measured as a function of
retained AP activity. Binding curves were fit using a one-site specific binding mode
to determine Kd (Graphpad Prism). Kd error is presented as the 95% confidence
interval.
Isothermal titration calorimetry
Peptides with sequence WDQKKPRNRR (S3F-RR) and WDQKKPRNPR (S3FPR) were synthesized by solid-phase synthesis and purified to >95% purity
(LifeTein, South Plainfield, NJ). Purified Nrp1-b1b2 and the S3F peptides were
exhaustively dialyzed against ITC buffer (10 mM phosphate, 238 mM NaCl, 2.7
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mM KCl, pH 7.4). Following dialysis, Nrp1 was concentrated to 40 μM and S3F
peptides were diluted to 390 μM as measured by OD280 (NanoDrop 1000, Thermo
Scientific).
Binding between Nrp1 and the S3F peptides was measured using a VP-ITC
Microcalorimeter (MicroCal, GE Healthcare) and data was processed with Origin
software (OriginLab, Northampton, MA). Nrp1-b1b2 was transferred into the
sample cell and the syringe was loaded with S3F. Sample measurements were
made at 30 °C and the system was set to provide a reference power of 10 μcal/sec.
Thirty 10 μl injections were made, spaced 250 sec. apart. To determine the heat
of ligand dilution, S3F-RR and S3F-PR were separately injected into ITC buffer
utilizing the same parameters as the experimental runs. The heat of ligand dilution
was subtracted from the heat of binding to generate a binding isotherm that was fit
with a one-site binding model in Origin, allowing determination of the association
constant (Ka), enthalpy (ΔH), and entropy (ΔS) of the interaction. K a was used to
calculate Kd (Kd=1/Ka). ITC data was collected in quadruplicate for each peptide
with independent preparations of Nrp1-b1b2.
Western blot analysis of Sema3F furin processing
The Ig-basic domains of human Sema3F (residues 605-785, S3F-Hgh), as well as
the single point mutant, R778P (R778P-Hgh), were cloned into the pLexM vector
(Aricescu et al., 2006) for expression with an N-terminal PTP-α signal sequence
and C-terminal Hgh fusion (Leahy et al., 2000). Protein was expressed by transient
transfection from CHO, furin deficient FD11, and furin overexpressing cells
(Gordon et al., 1995). Western blot analysis was performed on conditioned
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medium from all cell types to detect the Ig-basic-Hgh fusion protein (unprocessed)
or free Hgh (processed) as previously described (Parker et al., 2010). An anti-Hgh
polyclonal primary antibody (1:10000 dilution, RD1-HGHabrX1, Fitzgerald
Industries, Acton, MA) and anti-rabbit HRP secondary antibody (1:20000 dilution,
sC-2301, Santa Cruz Biotechnology, Santa Cruz, CA) were utilized and the blot
was developed using SuperSignal West Pico (Pierce Biotechnology, Rockford, IL).
Image Lab software (Bio-Rad Laboratories, Hercules, CA) was used to calculate
the percent of processed Ig-basic-Hgh relative to total protein.
Prism (Graphpad Software, La Jolla, CA) was used for analyzing and
graphing data and for calculating the statistical significance between sets of data
as determined by a student’s t-test. Molecular graphics were generated using
Pymol (The PyMOL Molecular Graphics System, Version 1.5.0.2 Schrödinger,
LLC).
AP-VEGF-A Recovery Assay
To measure the preferential binding of Nrp1 and Nrp2 to Sema3F or VEGF-A the
potential of Nrp to promote the recovery of C-furSema [19] mediated inhibition of
AP-VEGF-A binding to Nrp1 was assessed. Nrp1 and Nrp2 were combined with
both AP-VEGF-A (155 μmole p-NPP hydrolyzed/min/L) and C-furSema3F (45nM,
the concentration at which ≈90% inhibition is achieved) in incubation buffer and
added to low density Nrp1 affinity plates for 1hr at 25C. Plates were washed and
retained AP activity quantitated as described above. Retained AP-VEGF-A was
reported versus Nrp concentration as the percent of binding observed relative to
uninhibited AP-VEGF-A (no C-furSema).
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Circular Dichroism
Circular dichroism (CD) spectra were collected using a Jasco J-810
Spectropolarimeter. Wild-type and chimeric proteins were added to a 0.1-cmpathlength cuvette at 10μM in PBS pH 7.4. Spectra were recorded at a speed of
20nm/min using the average of three accumulations over a range of 205-245 nm.
Data are reported as per residue molar ellipticity.

Copyright © Matthew W. Parker 2014
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CHAPTER 3: FURIN PROCESSING OF SEMA3F DETERMINES ITS ANTIANGIOGENIC ACTIVITY BY REGULATING DIRECT BINDING AND
COMPETITION FOR NRP
Introduction
Vertebrates employ a wide array of secreted growth factors and cell surface
receptors to regulate the growth and guidance of axons.

The semaphorins

represent one of the largest families of cytokines that directly guide axon growth
(Koncina et al., 2007; Zhou et al., 2008). There are five recognized families of
semaphorins in vertebrates, including the Sema3 family, all six members of which
are secreted and able to diffuse through tissues (Kolodkin et al., 1993). Nrp directly
binds to most Sema3 family members and is essential for axonal guidance (He
and Tessier-Lavigne, 1997; Nakamura et al., 1998).
Nrp interacts with members of the Sema3 family of ligands and functions
together with plexin family receptors in Sema3 mediated axon guidance (Fujisawa,
2004; Takahashi et al., 1999). Nrp also interacts with the VEGF family of ligands
and functions together with VEGFR family receptors in VEGF mediated
angiogenesis (Klagsbrun et al., 2002; Soker et al., 1998). Higher eukaryotes
possess two Nrp family members, Nrp1 and Nrp2, which share 44% amino-acid
sequence identity (Kolodkin et al., 1997). They both function in Sema3 and VEGF
signaling but differ in their substrate specificity among ligands and receptors, as
well as specific control of protein expression and recycling (Chen et al., 1997). In
vivo, Sema3F functions via Nrp2 to control axon guidance both in the CNS and
peripheral nervous system (Sahay et al., 2003).
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The coagulation factor domains of Nrp, b1 and b2, contain the high-affinity
binding site for both VEGF and the C-terminal domain of Sema3 (Giger et al., 1998;
Mamluk et al., 2002). Because Sema3 and VEGF share an overlapping binding
site within the b1 domain of Nrp, the role of Nrp in mediating interplay between the
two seemingly distinct pathways of VEGF dependent angiogenesis and Sema3
dependent axon guidance is the source of considerable interest. However, there
are conflicting reports as to the role and extent of ligand competition for Nrp
binding.
A number of researchers have observed direct competition between VEGF
and Sema3 (Gu et al., 2002; Miao et al., 1999; Narazaki and Tosato, 2006). This
is consistent with both VEGF and Sema3 families possessing a highly basic Cterminal domain that interacts with the b1 domain of Nrp. Additionally, multiple
Sema3 family members have been shown to have potent anti-angiogenic activity
in vivo (Adams et al., 1997; Christensen et al., 2005; Kessler et al., 2004).
Surprisingly, a number of other researchers have recently reported that
there is no competition between VEGF and Sema3 (Appleton et al., 2007; Vieira
et al., 2007). Previous studies defined the critical importance of a C-terminal
arginine residue in the binding of both VEGF and inhibitory peptides to Nrp
(Starzec et al., 2007; Teesalu et al., 2009; Vander Kooi et al., 2007; von Wronski
et al., 2006). The observed lack of ligand competition for Nrp is consistent with the
fact that no Sema3 family members possess a C-terminal arginine, and it has been
suggested that two distinct surfaces in the b1 domain of Nrp may be employed for
ligand binding.
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These conflicting reports suggest that a critical mechanistic feature of Nrp
ligand binding is not understood. This has motivated studies to determine the
physical mechanism for the interaction of Nrp and Sema3 and the basis for
Sema3’s observed anti-angiogenic activity. The immediate C-terminus of Sema3
is not well conserved and does not contain a C-terminal arginine residue (Figure
3.1, A).

However, a region just upstream of the C-termini is, in fact, highly

conserved and has been shown to be a cleavage site for the furin family of proprotein convertases. Proteolytic processing in Sema3’s C-terminal domain has
been shown to regulate the anti-angiogenic potency of several Sema3s, which has
been suggested to involve Nrp binding (Adams et al., 1997; Christensen et al.,
2005; Potiron et al., 2009). We hypothesized that proteolytic activation of the Cterminus of Sema3 may be critical for regulating interaction with Nrp.

We

demonstrate that Sema3F is proteolytically processed at its C-terminus. This
processing is essential for the production of a mature C-terminal region of Sema3F
that can physically interact with Nrp. Further, the mature form of Sema3 potently
blocks VEGF binding to Nrp. These data demonstrate that mature Sema3 and
VEGF ligands do compete for binding to the overlapping binding site in the b1
domain of Nrp, but that furin processing of Sema3 is essential for its physical
interaction and anti-angiogenic potency. These findings resolve conflicting results
in the literature by providing a physical basis for understanding the regulation of
Sema3 interaction with Nrp.

Further, these results open new avenues to

understand the cross-talk between neuronal and vascular guidance through ligand
competition for a shared co-receptor.
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Results
Sema3F is proteolytically processed in its C-terminal domain
Sema3F possesses an RXRR consensus furin-like protease recognition
sequence at its C-terminus. This region is highly conserved in five of the Sema3
family members (Figure 3.1, A).

To test whether Sema3F is proteolytically

processed in its C-terminus, we expressed the C-terminal Nrp binding region of
Sema3F (Ig-basic) with a C-terminal human growth hormone (Hgh) fusion. The
construct was expressed in CHO cells, FD11 CHO cells lacking furin activity, and
CHO cells overexpressing furin (Gordon et al., 1995).

Wild-type CHO cells

expressed a mixture of processed and unprocessed forms of Sema3F (Figure 3.1,
B). FD11 cells produced solely the unprocessed form of Sema3F, whereas furin
overexpressing cells produced only the processed form (Figure 3.1, B). To further
confirm that the observed proteolytic processing is the result of furin activity, the
construct was expressed in COS-7 cells. The protein was found to be >95%
processed (Figure 3.1, C). The observed proteolytic processing is fully blocked by
addition of furin inhibitors (Figure 3.1, C). Thus, as has been previously observed
with other Sema3 family members (Adams et al., 1997; Christensen et al., 2005),
Sema3F is proteolytically processed in its C-terminal basic domain.
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Figure 3.1: Furin processing of Sema3F.
A) Sema3 family members contain a conserved furin recognition sequence in their
C-terminus. B) A mixture of unprocessed (100 kDa) and processed (24 kDa) forms
of Sema3F-Hgh fusion are observed when overexpressed in CHO cells. Furin
deficient (FD11) cells produce only the unprocessed form, whereas furin
overexpressing cells produce only the processed form.

C) Sema3F-Hgh

expressed in COS-7 cells is nearly completely processed, whereas addition of furin
inhibitors produces almost complete reversal to the unprocessed form. Protein
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molecular weights were estimated using the Magic Mark XP molecular weight
standard (MW) (Invitrogen, Carlsbad, CA).

37

C-terminal processing of Sema3F regulates interaction with Nrp
A specific interaction has been shown between the C-terminus of Sema3F
and core ligand binding domains (b1b2) of Nrp2 (Giger et al., 1998). To determine
the effect of the observed proteolytic processing, we tested the ability of the
unprocessed and processed forms of Sema3F to interact with Nrp, utilizing a Nrp2
affinity pull-down of the C-terminus of Sema3F. In order to test the effect of the Cterminal sequence, a construct was produced with a native C-terminal sequence
and the Hgh attached to the N-terminus. Furin cleavage would remove only six
residues at the C-terminus and so, as expected, no difference in apparent
molecular weight is observed between N-terminally tagged protein expressed in
Cos-7 cells in the absence or presence of furin inhibitors. However, a dramatic
difference is observed in their ability to interact with Nrp2. The processed form of
Sema3F, expressed from COS-7 cells in the absence of furin inhibitors, shows a
robust interaction with the Nrp2 affinity resin (Figure 3.2, A).

This result is

consistent with previous reports describing the domain specific interaction
between the C-terminal Ig-basic domain of Sema3F and Nrp2 (Giger et al., 1998).
In contrast, the unprocessed form, expressed from Cos-7 cells in the presence of
furin inhibitors, shows little if any ability to interact with the Nrp2 affinity resin
(Figure 3.2, A). This result suggests that the mechanism underlying the profound
physiological effect of furin processing of Sema3 may be direct regulation of the
physical interaction between the C-terminus of Sema3 and the b1 domain of Nrp.
To more fully characterize the interaction of the C-terminus of Sema3 with
Nrp, we produced peptides from the C-terminus of Sema3F that include the C-
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terminal intermolecular disulfide and basic domain. This allowed production of a
pure, chemically defined species corresponding to the unprocessed (C-Sema, the
final 46 residues of Sema3F) and processed (C-furSema, the same with the final
six residues removed, thus possessing a C-terminal arginine) forms of Sema3F.
To quantitatively characterize the interaction of the two proteins, the binding
of FITC labeled C-furSema to Nrp2 was measured using fluorescence anisotropy.
Incubation with Nrp2 resulted in a significant increase in anisotropy consistent with
a decrease in the rotational diffusion of the bound complex. The observed binding
was well fit with a single site binding model (R2=0.99) and allowed determination
of the dissociation constant Kd=4.1±0.5 mM (Figure 3.2, B).
Based on these data, we conclude that furin mediated activation of Sema3F
is critical for the physical interaction of the C-terminus of Sema3F with Nrp2. This
likely represents an important regulatory mechanism since the furin family of proprotein convertases is differentially expressed in the developing brain (Zheng et
al., 1994), suggesting that processing of Sema3 is spatially regulated.
Binding of C-furSema to Nrp1
Sema3F functions with Nrp2 in axon guidance, but functionally blocks
VEGF-A binding to Nrp1 to block angiogenesis.

To determine the basis for

Sema3F anti-angiogenic activity, we first tested if C-furSema was also able to bind
to Nrp1.

The binding of FITC C-furSema to Nrp1 was determined using

fluorescence anisotropy as with Nrp2. Binding was again well fit with a single site
binding model (R2=0.99) and a dissociation constant Kd=2.2±0.2 μM (Figure 3.2,
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C). Thus, C-furSema can bind both to Nrp2 and Nrp1, the latter with slightly higher
affinity.
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Figure 3.2: Interaction of the C-terminus of Sema3F with Nrp2 and Nrp1.
A) Affinity purification of the Hgh-Sema3F C-terminus using Nrp2 affinity resin
demonstrates that only the protein with a furin processed C-terminus is efficiently
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pulled down. B) FITC C-furSema shows a significant increase in anisotropy when
bound to Nrp2, which is fit well with a single site binding curve. C) Nrp1 also binds
to FITC C-furSema with slightly higher affinity.
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Inhibition of VEGF binding
To test whether the observed anti-angiogenic activity of Sema3F is due to
direct competition with VEGF-A for binding to Nrp1, we developed a novel
inhibitory assay. This assay measures the ability of Sema3F to compete with
VEGF-A for binding to the core ligand binding domains (b1b2) of Nrp1. Nrp1 was
adsorbed to 96-well plates to which AP-tagged VEGF-A binds specifically. VEGFA binding could be competitively blocked using anti-angiogenic inhibitory peptides
or other blocking reagents. Bound AP-VEGF-A was quantitatively determined
using a colorometric p-NPP based assay (Figure 3.3, A).
C-furSema, representing the processed form of Sema3F, was able to fully
inhibit the binding of AP-VEGF-A to Nrp. C-furSema was found to be a very potent
inhibitor with an IC50=46 ± 3 nM (R2=0.9999) (Figure 3.3, B, green).

This

demonstrates that, in fact, Sema3F and VEGF-A do directly compete for binding
to the core ligand binding domains of Nrp, explaining the anti-angiogenic potency
of Sema3F in vivo.
To determine the effect of proteolytic activation of Sema3F on antiangiogenic potency, we tested the ability of C-Sema to competitively block VEGFA binding to Nrp.

C-Sema, representing the unprocessed form of Sema3F,

showed no inhibition of VEGF-A binding even at high concentrations (Figure 3.4,
B, red).
These results underline the essential importance of furin processing of
Sema3, and provide a mechanism for the observed anti-angiogenic potency of
Sema3F. In summary, we demonstrate that furin processing produces a form of
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Sema3F that binds to the core ligand binding domains of Nrp and directly
competes with VEGF-A for receptor binding. Since processing occurs within the
Sema3F basic domain, proteolysis may also regulate Sema3’s ability to interact
with the ECM, such as is seen for VEGF-A. Indeed, specific glycosaminoglycans,
components of the ECM, have been shown to interact with Sema3, VEGF, and
Nrp and are known to be important mediators of angiogenesis and neuronal axon
guidance (Dick et al., 2013; Stringer, 2006; Vander Kooi et al., 2007).
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Figure 3.3: C-furSema potently inhibits VEGF-A binding to Nrp.
A) Design of a novel plate based inhibition assay measuring the displacement of
AP-tagged VEGF-A from Nrp1 b1b2 coated plates with increasing concentration
of peptide. B) C-furSema potently inhibits the binding of AP-VEGF-A to Nrp1 with
an IC50=45nM (green).

C-Sema shows no inhibitor potency even at high
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concentrations (red). Each point is the average of three independent samples with
error bars representing +/- one standard deviation.
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Discussion
We demonstrate that Sema3F is proteolytically processed at its C-terminus.
This processing is essential for the interaction of Sema3F with the core ligand
binding domains of Nrp. Our data provides a physical explanation for this, since
furin processing liberates a C-terminal arginine.

Possession of a C-terminal

arginine has been demonstrated to be critical for the interaction of both VEGF and
peptide inhibitors with Nrp (Starzec et al., 2007; Vander Kooi et al., 2007). Further,
the b1 domain of Nrp is utilized for binding both VEGF and Sema3 families of Nrp
ligands, yet the nature of the different ligand interactions with and competition for
Nrp has been unclear. We demonstrate that the two classes of ligands directly
compete for Nrp binding, but only when Sema3 is processed. A C-terminal peptide
representing the proteolytically processed form of Sema3F potently blocks the
binding of VEGF to Nrp, explaining the anti-angiogenic activity of Sema3F (Figure
3.4).
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Figure 3.4: Model for the mechanism of anti-angiogenic activity of Sema3F.
Our data demonstrates that furin dependent activation of the C-terminus of
Sema3F is essential for direct interaction with Nrp and anti-angiogenic activity via
competition with VEGF-A for binding to the b1 domain of Nrp.
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Understanding the mechanistic basis for the interaction of the C-terminus
of Sema3 with Nrp also provides a simple yet elegant explanation for the divergent
literature reports regarding the competition of VEGF and Sema3 ligands for Nrp
binding. C-terminal fusions, such as Fc or AP, are often used in the expression
and purification of Sema3 family members. This includes commercially available
Sema3s, which are expressed and purified using a C-terminal Fc-fusion (R & D
Systems). These proteins represent solely the unprocessed form of Sema3 and,
as expected from our studies, are unable or have dramatically decreased ability to
compete with VEGF for binding to Nrp. When using a C-terminal tag, such as AP,
for quantitation but not purification, the protein produced will likely be a mixture of
the processed and unprocessed forms. When using an N-terminal tag, care should
be taken since proteolytic processing of the C-terminus does not produce an
appreciable shift in molecular weight and thus a mixture of processed forms will be
produced unless furin activity is specifically inhibited or enhanced. It is interesting
to note that Sema3F produced in wild-type CHO cells has a larger percentage of
unprocessed protein, whereas that produced in COS-7 cells is almost completely
processed. In vitro, the ratio of processed to unprocessed Sema3 will be highly
dependent on the cell type used to express the protein. In vivo, cell and tissuespecific proteolytic processing of Sema3 family members may well represent an
important mechanism controlling the production of anti-angiogenic Sema3s.
The role of proteolytic processing of the C-terminus of Sema3F is the
simplest case for the Sema3 family, since it possesses a single furin consensus
site in its C-terminus. Other family members have additional furin-like consensus
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sites. For instance, it has been demonstrated experimentally that Sema3A can be
processed at three different sites in its final forty-five residues (Adams et al., 1997).
It will be interesting to determine if proteolytic processing at these different sites
produces proteins with differing anti-angiogenic potency.
Paradoxically, it has been shown that furin processing of Sema3B can
inactivate its anti-angiogenic potency (Varshavsky et al., 2008). However, the
observed cleavage is at a known site in the middle of the Sema3 gene, upstream
of the Ig domain, and removes the entire Ig-basic region, including the cysteine
that forms the critical intermolecular disulfide essential for Sema3 function
(Kolodkin et al., 1993). Thus, proteolytic processing of Sema3 can either activate
or inactivate its anti-angiogenic potency, depending on the site of proteolysis.
The difference between the observed direct binding affinity of C-furSema to
Nrp and its inhibitory potency in blocking VEGF binding to Nrp is of interest. The
observed binding affinity of C-furSema for Nrp (2.2 mM) is comparable to those
reported for VEGF binding to Nrp1 (2 mM) by surface plasmon resonance with low
Nrp density (Fuh et al., 2000). However, VEGF binding to Nrp has been shown to
be highly dependent on Nrp density, with four fold higher density of Nrp leading to
a twenty-fold increase in apparent affinity (Fuh et al., 2000). The higher potency
of inhibition observed in our plate-based inhibitory assay is consistent with this
result, since maximal amounts of Nrp are coupled to the plate. C-furSema’s
inhibitory potency in the plate based assay is thus likely due to avidity affects of
the dimeric ligand binding to two Nrp molecules, and accurately reproduces the
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inhibitory potency of previously reported peptides measured both in vitro and in
situ.
These data establish Sema3 C-terminal proteolysis as an essential
mechanism regulating Sema3 binding to the Nrp coagulation factor domains.
Interestingly, C-terminal proteolysis across the Sema3 family is predicted to
generate ligands with divergent C-terminal sequence. Thus, one exciting area for
future research is aimed at determining whether furin proteolysis can liberate
specific sequence elements upstream of the non-variant C-terminal arginine as a
mechanism to modulate Sema3/Nrp affinity.

Reprinted in full or part with permission from: Furin processing of semaphorin
3F determines its anti-angiogenic activity by regulating direct binding and
competition for neuropilin. Matthew W. Parker, Lance M. Hellman, Ping Xu,
Michael G. Fried, and Craig W. Vander Kooi, Biochemistry 2010 49 (19), 40684075. Copyright 2010 American Chemical Society.
Copyright © Matthew W. Parker 2014
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CHAPTER 4: EFFECT OF C-TERMINAL SEQUENCE ON COMPETITIVE
SEMA3 BINDING TO NRP1
Introduction
The Nrp family of type I transmembrane receptors coordinate critical
signaling events in the cardiovascular and nervous system where they are
essential in development, homeostasis, and pathogenesis. The two families of
canonical Nrp ligands are the VEGF family of pro-angiogenic cytokines and the
Sema3 family of axon guidance molecules (rev. in (Parker et al., 2012a)). VEGF
signaling via Nrp and a VEGFR receptor tyrosine kinase family member is
essential for physiological and pathological angiogenesis and plays a causative
role in tumorigenesis (rev. in (Carmeliet, 2005; Ellis, 2006)) and wet macular
degeneration (Cui et al., 2003; Rosenfeld et al., 2006). Additionally, it has recently
been shown that Nrp is critical for autocrine cancer stem cell activation and
maintenance (Beck et al., 2011; Goel et al., 2013). Sema3 signaling via Nrp and
Plexin receptors mediates physiological axon guidance and contributes to
pathological axon repulsion following CNS injury (rev. in (Hota and Buck, 2012;
Niclou et al., 2006)).
Because of its role in multiple pathological conditions, Nrp represents an
attractive therapeutic target. Peptides (Parker et al., 2010; Starzec et al., 2006;
von Wronski et al., 2006), peptidomimetics (Jarvis et al., 2010), soluble receptor
fragments (Gagnon et al., 2000), and monoclonal antibodies (Appleton et al., 2007;
Liang et al., 2007; Pan et al., 2007a) have all been explored as Nrp binding and
blocking molecules. Peptides are the best-studied class of Nrp targeting and
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modulating molecules and have been developed not only for their competitive
ligand binding activity but also for other diverse purposes including in vivo Nrp
diagnostic imaging (Benachour et al., 2012; Perret et al., 2004) and for cargo
targeting to Nrp-expressing tumors (Roth et al., 2012; Teesalu et al., 2009). Nrp
ligand-blocking peptides include sequences derived from endogenous Nrp ligands
(Jia et al., 2006; Parker et al., 2010), the naturally occurring immunostimulatory
peptide Tuftsin (von Wronski et al., 2006), and phage-display derived peptides
(Starzec et al., 2006; Teesalu et al., 2009). Initial mechanistic and developmental
work has provided critical insights into Nrp ligand binding, but additional insights
are needed to produce peptides that are optimized for potency, selectivity, and
stability.
Biochemical and structural approaches have demonstrated that all known
Nrp ligands require a C-terminal arginine (CR) for binding to a conserved pocket in
the Nrp b1 domain (Delcombel et al., 2013; Parker et al., 2010; Parker et al., 2012c;
Vander Kooi et al., 2007). Alternative splicing generates a CR in many VEGF
families, including VEGF-A (rev. in (Harper and Bates, 2008)) and VEGF-B
(Olofsson et al., 1996b), but proteolytic maturation is required in the case of VEGFC and VEGF-D (Karpanen et al., 2006). Similarly, Sema3 family members require
proteolytic activation by furin-family proteases to liberate a CR (Adams et al., 1997;
Christensen et al., 2005; Varshavsky et al., 2008) that then allows them to function
as endogenous competitive inhibitors of Nrp, as demonstrated in Chapter 3 (Gu et
al., 2002; Miao et al., 1999; Parker et al., 2010). Indeed, relative levels of VEGF
and Sema3 family members have been shown to critically contribute to

53

tumorigenesis (Bender and Mac Gabhann, 2013; Serini et al., 2013). Furin family
proteases cleave substrates following an arginine residue (Hosaka et al., 1991).
There are between one and three canonical RXXR furin cleavage sites in the Cterminal basic domain of Sema3 family members, producing Sema3 ligands with
alternative forms of the C-terminal domain (Adams et al., 1997).
All known peptide inhibitors of Nrp also contain a CR and target the
conserved Nrp-b1 pocket, binding in a mode analogous to that of Nrp ligands (Jia
et al., 2006; Starzec et al., 2007; Teesalu et al., 2009). Recently, the structural
basis for CR dependent Nrp binding has been described. Crystal structures of the
VEGF-A heparin binding domain (HBD) (Parker et al., 2012c) and Tuftsin (Vander
Kooi et al., 2007) in complex with Nrp1 revealed a shared mode of receptor
engagement and have provided critical insight into the physical basis for Nrp
binding. Two residues of the ligand contribute to Nrp-b1 binding. The CR is critical
for Nrp binding and mediates the majority of the interface via divalent engagement
of both the CR side chain and carboxylate at the C-terminus (Parker et al., 2012c).
The third-to-last residue (denoted as residue-“C-2” hereafter) mediates the other
interaction, with the C-2 backbone carbonyl forming a hydrogen bond with the
aromatic hydroxyl of Nrp1-Y297. This interaction is also critical since mutation of
Y297 results in loss of ligand binding (Herzog et al., 2011). That this interaction
critically depends on a backbone hydrogen bond is supported by the observation
that for ATWLPPR, Nrp binding is C-2 sequence-independent but truncation
smaller than a tetrapeptide eliminated activity (Starzec et al., 2007). While a CR
residue is critical for all peptide inhibitors of Nrp, no upstream consensus has been
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identified. This led us to investigate the sequence-dependence for Nrp-ligand
binding and inhibition.
To determine the role of residues upstream of the CR, we studied the
sequence dependence of Nrp binding and inhibition of Sema3F derived peptides.
We found that the C-1 residue serves the critical role of positioning the CR and C2 residues to allow concurrent Nrp binding. A peptide library with substitution of
all 20 natural amino acids at the C-1 position revealed that residues that naturally
adopt an extended conformation enhance inhibitory potency by six-fold. A C-1
proline produced the most potent Nrp binding peptide, which we demonstrate is
due to a specific reduction in the entropic cost of binding. We further demonstrate
that there is an inverse relationship between furin processing of Sema3 and
inhibitory potency across the Sema3 family. These data provide critical insight into
the mechanism of Nrp ligand binding and potent inhibition, and describe a novel
mechanism for regulated Sema3 furin processing and Nrp receptor engagement.
Results
C-1 sequence variation critically affects peptide potency
To determine the contribution of the C-1 residue to Nrp binding and
inhibitory potency, a peptide library derived from the C-terminal domain of Sema3F
(WDQKKPRNRR) was synthesized with all twenty natural amino acids substituted
at the C-1 position. The library was tested for the ability to inhibit alkaline
phosphatase (AP)-tagged VEGF-A binding to Nrp1 utilizing an in vitro plate-binding
assay. Retained AP-VEGF-A was measured as a function of peptide
concentration. For all peptides, full AP-VEGF-A inhibition was achieved and the
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concentration of peptide resulting in half AP-VEGF-A inhibition (IC50) was
determined. Significant differences in inhibitory potency were observed, with wild
type Sema3F (S3F-RR, black line, IC50 = 11 μM) showing intermediate potency
between the peptides with maximum and minimum potency, C-1 proline (S3F-PR,
green line, IC50 = 4.7 μM) and C-1 aspartate (S3F-DR, red line, IC50 = 28 μM)
peptides, respectively (Figure 4.1, A).
Sequence alteration at the C-1 residue resulted in a significant variation in
peptide potency (Figure 4.1, B), indicating that this position plays a significant role
in modulating Nrp binding. The most potent inhibitor was the C-1 proline peptide,
which was six times more potent than the aspartate variant. Analysis of previously
published peptide inhibitors reveals a preference for proline at the C-1 position.
Modified Tuftsin (TKPPR) and the phage display derived peptide ATWLPPR
possess a C-1 proline. The prototypic CendR peptide identified by phage display,
RPARPAR, does not have this sequence element. However, an analysis of the
other CendR peptides that were initially identified reveals that 30% of all peptides
contained a C-1 proline, in striking contrast to the 5% theoretical representation if
there were no selective pressure at the C-1 position (Haspel et al., 2011).
Collectively these data reveal a significant role for the C-1 position in determining
competitive binding to Nrp.
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Figure 4.1: Inhibitory potency of C-1 peptide variants.
(A) Peptides were titrated to determine their inhibitory potency versus AP-VEGFA. Shown are representative inhibition curves for wild type peptide (S3F-RR, black
line) and the variants with maximum and minimum potency, S3F-PR (green line)
and S3F-DR (red line), respectively. (B) Table of all C-1 variants with their
respective IC50. Values are reported as the mean ± standard deviation
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Potency is correlated with the propensity of the C-1 residue to adopt an
extended conformation
Intriguingly, the identity and chemical properties of the C-1 residue,
including charge and hydrophobicity, seemed to have little systematic impact on
potency. Structural analysis indicates that the C-1 side-chain is dynamic and
shows little if any direct interaction with Nrp. Instead, we hypothesized that the C1 residue critically tethers the C-2/Nrp1-Y297 hydrogen bond with the CR mediated
salt-bridge and hydrogen bond network. Using structures of Nrp1 complexes, we
measured the backbone torsion angles of the C-1 Tuftsin (PDB=2ORZ) and VEGFA (PDB=4DEQ) residue to determine whether a specific orientation is required to
tether the adjacent CR and C-2 interaction interfaces. Although VEGF-A contains
a C-1 arginine and Tuftsin a C-1 proline, residues with markedly different
physiochemical properties, their backbone conformations were very similar (Figure
4.2, A). Analysis of the backbone dihedral angles demonstrate that they lie within
the extended region of the Ramachandran plot with Φ,Ψ=-89°,108° and -85°,158°,
respectively (Figure 4.2, B).
The extended conformation seen for both proline and arginine indicates that
residues with an inherent propensity to adopt an extended conformation could,
when present at the C-1 position, enhance Nrp binding. Upon analysis of all
variants, it was striking to observe that proline and β-branched amino acids
(isoleucine, valine and threonine) produced the most potent C-1 variants (Figure
4.1, B). We examined the relationship between the IC50 for each C-1 variant and
the Chou-Fasman β-sheet propensity scale for each amino acid (Fasman, 1989)
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to determine whether these properties are correlated (Figure 4.2, C). Indeed,
potency and β-sheet propensity showed a highly significant correlation (correlation
coefficient (r) = -0.74, p = 0.0003). These data support a correlation between
competitive potency and preferred C-1 backbone conformation.
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Figure 4.2: The C-1 residue of Nrp1 ligands adopts an extended backbone
conformation.
(A) Superimposition of the product bound structures of VEGF-A (green)
(PDB=4DEQ) and Tuftsin (gold) (PDB=2ORZ) in complex with Nrp1 (PDB=2ORZ).
There are two distinct interaction interfaces, one of which is mediated by the CR
and the other by the C-2 carbonyl of the ligand. The C-1 residue serves the critical
role of tethering the adjacent interacting residues and correctly orienting them with
respect to one another within the binding pocket. (B) Ramachandran plot of the Φ
and Ψ angles of the C-1 VEGF-A (C-1 R) and Tuftsin (C-1 P) residue reveals that
they adopt an extended conformation. (C) Plotting the IC 50 for each C-1 variant
against the β-sheet propensity of each amino acid reveals a correlation between
potency and the inherent preference of amino acids to adopt an extended
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conformation. Proline was excluded from the fit due to its inability to conform to the
backbone hydrogen bonding pattern present in β-sheets and, therefore, its low βsheet propensity.
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Preferential backbone conformation minimizes the entropic cost
associated with binding
Thus, we hypothesized that peptides with a C-1 residue that inherently
favors an extended conformation would have increased potency due to decreased
entropic cost associated with Nrp1 binding.
thermodynamic

parameters

of

S3F-RR

Therefore, we measured the

(WDQKKPRNRR)

and

S3F-PR

(WDQKKPRNPR) binding to Nrp1 using isothermal titration calorimetry (ITC).
With Nrp1 in the sample cell, peptides were titrated to saturation and the
resulting binding isotherms were fit with a one-site binding model, allowing
determination of thermodynamic binding parameters. S3F-RR (Figure 4.3, A) and
S3F-PR (Figure 4.3, B) fit to a 1:1 stoichiometry, consistent with a single CR ligand
binding to monomeric Nrp1. S3F-RR bound to Nrp1 with a Ka=3.0 x 104 M-1 (Kd =
33 μM) and S3F-PR bound with significantly higher affinity, with a Ka=10.1 x 104
M-1 (Kd = 10 μM). The binding enhancement for S3F-PR relative to S3F-RR is
consistent between direct binding and inhibitor potency (3.0-fold and 2.3-fold,
respectively). Binding of the less potent wild-type S3F-RR was actually more
favorable enthalpically (ΔH = -18.5 and -17.0 kcal/mole, for S3F-RR and S3F-PR,
respectively, p = 0.04). However, there was a significantly larger loss of entropy
upon S3F-RR binding as compared to S3F-PR binding (TΔS = -12.2 and -10.0
kcal/mole for S3F-RR and S3F-PR, respectively, p = 0.009). Thus, the difference
in entropy accounts for the preferential binding potency of S3F-PR.
The measured thermodynamic parameters of binding represent the
combined changes for both Nrp1 and the peptide upon binding. No significant
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differences in the orientation of the bound product in the Nrp b1 binding site (Figure
4.2, A), conformation of the Nrp1 binding pocket itself (R.M.S.D. = 0.6Å for C over
residue range 274-429), or protonation state have been indicated. Thus, the
difference in entropy between S3F-RR and S3F-PR binding can be best
interpreted in terms of conformational bias in the free ligand. Indeed, it was recently
suggested that peptide backbone rigidity is able to enhance Nrp binding (Zanuy et
al., 2013). These data directly support the hypothesis that proline substitution at
the C-1 position enhances Nrp binding by preferentially positioning the free peptide
backbone in a ligand bound-like extended conformation that allows engagement
of the C-2 and CR interactions. With proline at the C-1 position the backbone is
pre-organized for optimal receptor engagement.
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Figure 4.3: Analysis of peptide binding by ITC.
Using ITC the thermodynamic parameters of Nrp1 binding were measured for wild
type peptide (S3F-RR, A) and the C-1 proline variant (S3F-PR, B). A
representative binding isotherm is shown for each peptide. Values are reported as
the mean ± standard deviation of four independent experiments.
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Arginine is conserved at the C-1 position in Sema3F to maintain efficient
proteolytic maturation
Although a C-1 proline residue confers an advantage for Nrp1 binding, the
majority of furin consensus sequences present in Sema3 family members possess
a C-1 arginine residue. This opens the question of why arginine, as opposed to
proline, is preferred at the C-1 position of Sema3 family members. The Sema3
family of ligands require processing by furin family proteases for biological
function(Adams et al., 1997). This processing event liberates a CR and is required
for Nrp1 binding (Parker et al., 2010). We hypothesized that the C-1 residue may
directly affect furin-dependent proteolysis.
To test this hypothesis, we expressed the Sema3F Ig-basic domains with a
C-terminal human growth hormone (Hgh) fusion as either the wild type sequence
(S3F-Hgh) or with the C-1 residue mutated to proline (R778P-Hgh) (Figure 4.4, A).
S3F-Hgh and R778P-Hgh were secreted at similar levels, but processing by furin
was significantly different (Figure 4.4, B). When expressed in wild type CHO cells,
over 40% of S3F-Hgh protein was cleaved but only 10% of R778P-Hgh could be
processed. No processing was observed for either S3F-Hgh or R778P-Hgh when
expressed in CHO cells deficient in furin activity (FD11) (Gordon et al., 1995),
demonstrating that the observed processing is due to furin activity. In contrast, in
CHO cells stably overexpressing furin (Gordon et al., 1995), the majority (70%) of
secreted S3F-Hgh was furin processed, while 30% of R778P-Hgh was processed.
These data demonstrate that a C-terminal di-arginine motif allows optimal
proteolysis by furin family proteases and that variation at the C-1 position alters
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proteolytic efficiency. It is notable that R778P-Hgh is partially processed and that
this processing increases in cells with higher levels of furin activity. Thus, tissue
specific differences in furin activity or differential expression of different proprotein
convertase (PPC) family members may serve as a regulatory mechanism
underlying activating proteolysis of the different furin sites.
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Figure 4.4: Mutation of the Sema3F C-1 residue alters processing
efficiency.
(A) The Ig-basic domains of Sema3F were expressed as a C-terminal Hgh fusion.
In addition to wild type protein (S3F-Hgh), a mutant with the C-1 arginine residue
of the furin consensus site mutated to proline (R778P-Hgh) was expressed. The
arrow indicates the site of furin proteolysis. (B) S3F-Hgh and R778P-Hgh were
expressed in CHO, furin deficient (FD11), and furin over expressing (Furin) cells
and the efficiency of processing was measured by blotting for Hgh. S3F-Hgh was
processed in CHO and Furin cells, as detected by the presence of the processed
form, but significantly less processing was seen for R778P-Hgh in these cell types.
Neither construct was processed in FD11 cells.
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C-1 variation in the Sema3 family alters Nrp1 binding
Sema3F contains a single furin proteolysis site in its C-terminus. This site
has a strong furin consensus (KXRXRR) and is conserved in five of the seven
Sema3 family members (Figure 4.5, A, site 2). While it is clear that this extended
basic sequence serves as an ideal furin substrate, different Sema3 family
members possess up to two other furin sites that have a conserved dibasic RXXR
motif (Molloy et al., 1992; Watanabe et al., 1993) and have been demonstrated to
be processed (Adams et al., 1997; Christensen et al., 2005; Varshavsky et al.,
2008). For all family members, cleavage at the first and second furin site results in
a C-1 arginine, while processing at the third site results in a C-1 P residue (Figure
4.5, B). By aligning the terminal four amino acids of all Sema3 family members,
the differential usage of arginine and proline at the C-1 position is clearly illustrated
(Figure 4.5, C) indicating two distinct classes of furin cleavage sites.

68

Figure 4.5: Furin proteolysis of Sema3 generates divergent C-terminal
sequences.
(A) The Sema3 family of ligands are furin processed at multiple sites within their
C-terminus that result in either a C-terminal arginine-arginine motif (site 1 and 2)
or a proline-arginine motif (site 3). (B) Peptides corresponding to all furin cleavage
sites (black arrow) within the basic domain of Sema3 family members were
synthesized with a leading tryptophan (grey). Sema3 variants are labeled
according to family member (A-G) and cleavage site number (1-3). (C) An
alignment of the four C-terminal residues of all Sema3 peptides illustrating the
either-or preference for proline and arginine at the C-1 position. The height of the
amino acids at each position represents their relative conservation within the
alignment.
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We tested the VEGF inhibitory potency of peptides representing all forms
of each member of the Sema3 family and found very significant differences.
Greater than a 40-fold difference was observed between the different Sema3
family members and an 18-fold difference between different sites in the same
Sema3 family member (Sema3A) (Figure 4.6, A). Sema3E.3 was the most potent
inhibitor with an IC50 = 0.76 μM and Sema3A.2 was the weakest inhibitor with an
IC50 = 34 μM. Notably, all peptides with a C-1 proline were more potent than all
peptides with a C-1 arginine (Figure 4.6, A). Indeed, when grouped by their C-1
residue (Figure 4.6, B), peptides with a C-1 arginine had a mean potency of 19 ±
11 μM, as opposed to peptides with a C-1 proline that had a mean potency of 2.4
± 1.4 μM (p = 0.02). Otherwise, no correlation between potency and sequence,
equivalent to that for the C-1 residue, was observed at other upstream positions.
This does not rule out additional secondary effects, since a range of IC50 values
are observed within the two C-1 groups. For instance, it is interesting to note that
furin processing at site 2, the most conserved in the Sema3 family, always
produces a C-2 asparagine (Figure 4.5, B), and these peptides showed the
weakest VEGF inhibitory potency (Figure 4.6, A). A strongly negative preference
for aspartate/asparagine is observed in the C-1 position (Figure 4.2, C), and it may
be that the sidechain of an asparagine residue in either the C-1 or C-2 position
competes with Nrp for mainchain interactions, thereby lowering affinity.
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Figure 4.6: Sema3 family variation in potency is explained by the C-1 amino
acid.
(A) The ability of all Sema3 ligand variants to inhibit VEGF-A binding to Nrp1 was
measured. The data are reported as the mean IC50 ± standard deviation. (B) The
IC50 for each peptide was plotted against the amino acid present at the C-1
position. Peptides with a C-1 proline (average IC50 = 2.4 ± 1.4 μM) were
significantly more potent than those with a C-1 arginine (average IC50 = 19 ± 11
μM). (C) The C-1 residue inversely effects furin consensus strength and Nrp
affinity.
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Discussion
Cumulatively, these data demonstrate that there is an inverse relationship
between furin processing and Nrp binding. While a C-1 arginine is best suited for
furin processing, a C-1 proline is best suited for Nrp1 engagement. Intriguingly,
while the majority of furin sites in the different Sema3 family members have a C-1
arginine, those without an arginine exclusively possess a proline residue at this
position, suggesting a possible tissue-specific regulatory mechanism of Sema3
activity.
While furin processing is critical, a differential physiological role and how
processing at the distinct sites is regulated is currently unknown. These data
indicate that there are two physically distinct classes of non-equivalent furin sites
in the C-terminal domain of Sema3 family members that are differentiated by their
C-1 residue. Indeed, it has been demonstrated within the context of full-length
protein that Sema3A cleaved solely at site 3 (Sema3A.3) shows maximal potency
and that when processing at this site is abolished, function is markedly reduced in
situ (Adams et al., 1997). Additionally, conformational flexibility may be important
for productive assembly of the Sema3 signaling complex, as suggested by the
recent structural characterization of the Nrp1/Sema3A/PlexinA2 complex (Janssen
et al., 2012). Differential furin processing could modulate the interdomain distance
between the Sema3 sema domain and basic domain C R, which engage Nrp a1
and b1 domains, respectively (Parker et al., 2012a; Parker et al., 2012b). It is
interesting to note that Sema3A.3 is the most potent sequence as well as the most
C-terminal furin site opening the possibility for coupling between binding site
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sequence and spacing. Thus, in physiological context, processing at the different
sites can produce different amplitude of Sema3 signaling, thereby providing a
mechanism for control of Sema3 signaling by regulation of both expression and
selective processing.
These data demonstrate that the C-1 position of Nrp binding peptides and
ligands is critical for regulating both potency and processing. This provides insight
into the mechanism of potent Nrp-binding and inhibition and lays the groundwork
for continued improvements to the potency and specificity of peptide inhibitors of
Nrp. Further, by studying the C-1 residue in the context of the C-terminus of
Sema3 we have gained an understanding of physiological Sema3 ligand function.
Interestingly, the Sema3 basic domain contains three non-equivalent furin
processing sites defined by possessing either a C-1 Arg or Pro. These data define
an inverse relationship between processing and potency, providing an important
new mechanism for post-translational regulation of Sema3 activity.

It was

previously thought that furin processing simply functioned as a binary activation
mechanism. However, our data indicates that the coupled relationship between
differential furin processing and Nrp engagement allows production of Sema3
forms with a range of biological activities (Figure 4.6, C). This provides insight into
the mechanistic basis for functional differences for Sema3 both in situ and in vivo.
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CHAPTER 5: STRUCTURAL BASIS FOR NRP2 FUNCTION AS A VEGF-C
RECEPTOR
INTRODUCTION
The VEGF family of cytokines are critical regulators of endothelial cell
function. There are five VEGF family members: VEGF-A, -B, -C, -D and placental
growth factor (PlGF). Of these five, VEGF-C and VEGF-D selectively control
lymphangiogenesis. While they show partially overlapping biological activity and
physical properties, VEGF-C is essential for viability while VEGF-D is not (Baldwin
et al., 2005; Karkkainen et al., 2004). Endothelial cells of homozygous VEGF-C
knockout mice do not sprout to form lymphatic vessels, which results in an
alymphatic embryo and embryonic lethality

(Karkkainen et al., 2004).

Overexpression of VEGF-C results in selective induction of lymphatic but not
vascular endothelial cell proliferation and lymphatic vessel enlargement (Jeltsch et
al., 1997). In addition to its critical physiological role, VEGF-C signaling is also
important for pathological lymphangiogenesis that is associated with both aberrant
loss of function in lymphedema (Saaristo et al., 2002) or gain of function in
tumorigenesis and metastasis (Caunt et al., 2008; Ellis, 2006; Stacker et al., 2002).
VEGF-C signals via the coordinated activity of two families of endothelial
cell surface receptors, the VEGFR family of receptor tyrosine kinases (RTK) (rev.
in (Stuttfeld and Ballmer-Hofer, 2009)) and the Nrp family of co-receptors (rev. in
(Parker et al., 2012a)). VEGF-C function is specifically mediated through VEGFR2/3 (Joukov et al., 1996; Kukk et al., 1996; Lymboussaki et al., 1999) and Nrp2
(Karkkainen et al., 2001; Xu et al., 2010), with VEGF-C capable of simultaneously
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engaging both families of receptors (Favier et al., 2006). VEGFR-2/3 have dual
functionality in both angiogenesis and lymphangiogenesis (rev. in (Lohela et al.,
2009)).

In contrast, Nrp2 knockout mice display normal angiogenesis but

abnormal lymphatic vessel development (Yuan et al., 2002), similar to the tissue
specific function observed in the VEGF-C knockout (Karkkainen et al., 2004).
Intriguingly, it has also been demonstrated that Nrp2 can function in VEGF-C
signaling independent of its role as a co-receptor for VEGFR (Caunt et al., 2008).
Each member of the VEGF family of ligands is produced in multiple forms
by either alternative splicing (e.g. VEGF-A, -B, and PlGF) or proteolytic processing
(e.g. VEGF-C and -D) (Holmes and Zachary, 2005). In all cases, an invariant core
cystine-knot domain, which specifically interacts with VEGFR, is combined with a
variable C-terminal domain. VEGF-C is synthesized as a pro-protein with N- and
C-terminal domains flanking the central core cystine-knot domain. Prior to
secretion, the C-terminal propeptide is cleaved followed by extracellular cleavage
of the N-terminus (Joukov et al., 1997). These processing events critically alter
both the physiological and pathological bioactivity of VEGF-C. The mature dual
processed VEGF-C shows dramatically enhanced stimulatory activity in situ
(Joukov et al., 1997; McColl et al., 2003) and loss of C-terminal processing ablates
function in vivo (Khatib et al., 2010). However, the physical basis for the enhanced
activity of the mature form of VEGF-C remains unclear and has been connected
to different properties including differential receptor binding and interactions with
heparin/extracellular matrix (ECM) (Harris et al., 2013; Joukov et al., 1997;
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Karpanen et al., 2006). The role of VEGF-C proteolytic maturation in regulating
Nrp2 binding is unknown.
The structural basis for VEGF-C binding to VEGFR-2/3 has recently been
elucidated and was shown to involve the invariant cystine-knot domain of VEGFC binding to the N-terminal domains of VEGFR-2 and VEGFR-3 (Leppanen et al.,
2010; Leppanen et al., 2013). However, the structural basis for VEGF-C binding
to Nrp2 remains to be determined. Alternative splicing and proteolysis modify the
C-terminal variable region of VEGF and regulate Nrp binding (Makinen et al., 1999;
Parker et al., 2012c; Soker et al., 1998). It has been demonstrated that Nrp1 binds
the C-terminal basic domain of Sema3 and VEGF family of ligands (He and
Tessier-Lavigne, 1997; Soker et al., 1996) utilizing a binding pocket for ligands that
contain a C-terminal arginine (Parker et al., 2010; Parker et al., 2012c; Vander
Kooi et al., 2007; von Wronski et al., 2006). As demonstrated in Chapters 3 and 4,
the Sema3 family of ligands undergoes furin-dependent proteolytic maturation
within their C-terminal domain, a process that liberates an extended basic
sequence and directly regulates bioactivity and Nrp binding (Adams et al., 1997;
Parker et al., 2010; Parker et al., 2013).
Nrp2-dependent VEGF-C signaling is important in a variety of tumors and
overexpression of these factors is correlated with advanced stage disease and
poor prognosis (Ellis, 2006; Stacker et al., 2002). Thus, specific Nrp2/VEGF-C
inhibitors are of clinical interest.

Soluble receptor fragments are common

endogenous inhibitors (Albuquerque et al., 2009; Ambati et al., 2006; Kendall and
Thomas, 1993; Rose-John and Heinrich, 1994). They can also be engineered for
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use clinically, including VEGF-trap (Aflibercept), a chimeric VEGFR-1/2-Fc fusion,
which is an inhibitor of VEGF-A (Holash et al., 2002). A soluble splice form of
Nrp2, s9Nrp2, has been identified at the transcript level (Rossignol et al., 2000).
s9Nrp2 is produced by intro inclusion, which contains an in-frame stop codon. This
stop codon is located prior to the transmembrane domain, and is thus predicted to
produce a secreted form of Nrp2. Interestingly, the insertion occurs in the middle
of the second coagulation factor domain (b2), rather than in an interdomain region.
The two Nrp2 coagulation factor domains (b1b2) form an integral unit (Appleton et
al., 2007) and thus the nature of the production and function of s9Nrp2 is unclear.
Further, domains b1b2 of Nrp2 have been demonstrated to bind VEGF-C
(Karpanen et al., 2006), bringing into question whether this soluble splice form
contains the structural requirements necessary to bind and sequester its ligands.
Here we demonstrate that removal of the VEGF-C C-terminal propeptide
directly regulates binding to Nrp2. The structure of the mature VEGF-C C-terminus
in complex with Nrp2 demonstrates that a cryptic Nrp2-binding motif is liberated
upon C-terminal processing. This offers the first structural insight into the physical
basis for VEGF-C binding to Nrp2, showing that the proteolytically liberated Cterminal arginine of VEGF-C directly binds the Nrp2 b1 domain. Mutagenesis of
both VEGF-C and Nrp2 confirms the critical nature of the VEGF-C C-terminal
sequence in Nrp2-b1 binding. Understanding the physical interactions underlying
VEGF-C/Nrp2 binding led us to consider mechanisms for VEGF-C inhibition. The
secreted Nrp2 splice form, s9Nrp2, contains an intact Nrp2 b1 domain but a
subsequent stop codon, and we assessed its function as a pathway specific
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inhibitor. Strikingly, this soluble receptor forms a disulfide-linked dimer with two
tightly integrated b1 domains and functions as a potent inhibitor of VEGF-C binding
to Nrp2.
RESULTS
Structural basis for proteolytic-dependent VEGF-C binding to Nrp2
VEGF-C is synthesized as a pro-protein with N and C-terminal propeptides.
Removal of the VEGF-C C-terminal propeptide critically regulates its bioactivity.
C-terminal processing of VEGF-C liberates a polypeptide stretch rich in basic
amino acids that terminates with a di-arginine sequence (Figure 5.1, A), a
structural motif conserved across the VEGF and Sema3 family of ligands and
known to be important for Nrp1 binding. Thus, we hypothesized that processing of
VEGF-C may directly regulate a physical interaction with Nrp2.

To test this

hypothesis, we produced peptides corresponding to the unprocessed (215RQVHSIIRRSLPA-227) and processed (215-RQVHSIIRR-223) VEGF-C Cterminus and measured the ability of each peptide to bind Nrp2 domains b1b2
using a differential scanning fluorimetry (DSF) thermal shift assay (Figure 5.1, B).
Processed VEGF-C significantly stabilized Nrp2-b1b2 (Tm 48.8°C ± 0.06°C to
50.3°C ± 0.05°C), while unprocessed VEGF-C showed no effect (Tm 48.4°C ±
0.04°C). Further, the processed VEGF-C peptide showed dose-dependent
saturable binding to Nrp2-b1b2 with an apparent dissociation constant (Kd) = 199
μM ± 71 μM (Figure 5.1, C). These data demonstrate that C-terminal proteolytic
maturation directly regulates VEGF-C binding to Nrp2.
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To define the physical basis for proteolytic-dependent binding of VEGF-C
to Nrp2, we determined the crystal structure of the processed VEGF-C C-terminus
in complex with Nrp2 domains b1b2. The C-terminal five amino acids of mature
VEGF-C (219-SIIRR-223), which are strictly conserved across species and also
with VEGF-D, were fused to the C-terminus of human Nrp2 domains b1b2
(residues 276-595). The fusion protein was expressed in E. coli, purified, and
crystallized. The structure was solved by molecular replacement and was refined
to a resolution of 1.9 Å (Figure 5.1, D, Table 1). Clear electron density for the
VEGF-C-encoded region was observed and manually built.

There were two

molecules in the asymmetric unit oriented in an anti-parallel fashion. Both
molecules demonstrated specific binding of the VEGF-C encoded residues via an
intermolecular interaction with a symmetry-related molecule.
Analysis of the structure reveals that VEGF-C (green) engages a binding
pocket formed by the Nrp2-b1 (blue) coagulation factor loops (Figure 5.1, D).
Indeed, this interloop cleft uniquely accommodates the C-terminal residue of
processed VEGF-C (Figure 5.1, E). The free carboxy-terminus of VEGF-C is
integrated into the binding pocket through interactions with residues from the third
coagulation factor loop (L3) of Nrp2-b1, which form a wall at one side of the binding
pocket (“C-wall”).

Specifically, an extensive hydrogen bond network forms

between the VEGF-C free C-terminal carboxylate and the side chains of the C-wall
residues S349, T352, and Y356 (Figure 5.1, E). Importantly, the position of the Cwall would preclude binding of the unprocessed protein, providing a physical
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mechanism for the observed proteolytic-dependent binding of VEGF-C to Nrp2b1b2.
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Figure 5.1: Crystal structure of the VEGF-C/Nrp2 complex reveals the basis
for proteolytic-dependent binding.
(A) Organization of the VEGF-C pro-protein and site of C-terminal processing
(black arrow). (B) Peptides corresponding to processed (green) and unprocessed
(black) VEGF-C were assayed for the ability to bind Nrp2-b1b2 as measured by
differential scanning fluorimetry (DSF) thermal shift assays. Peptides were added
to Nrp2-b1b2 to a final concentration of 0.5 mM and melting was monitored
between 20 and 90°C. All samples were measured in triplicate and a
representative melting curve is shown for each. (C) Processed VEGF-C dosedependently enhances the Nrp2-b1b2 Tm. Error bars indicate the standard
deviation of three measurements. (D) Structure of Nrp2-b1b2 (blue) in complex
with the C-terminus of VEGF-C (green). (E) Cross-section of the Nrp2 binding
pocket demonstrates that the free carboxy terminus of VEGF-C is buried against
the Nrp2 C-wall, which is formed by the third coagulation factor loop.
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Characterization of the VEGF-C/Nrp2 interaction
The clear electron density present at the Nrp2-b1 interloop cleft permitted
modeling of both the VEGF-C polypeptide and interfacing solvent that bridge the
two molecules (Figure 5.2, A). Analysis of the VEGF-C/Nrp2 interface reveals
direct interactions between VEGF-C and residues within the L1, L5, and L3 loops
of Nrp2-b1 (Figure 5.2, B). In addition to the hydrogen bond network formed
between the VEGF-C free carboxy-terminus and the Nrp2 L3 loop, the side chain
of the VEGF-C C-terminal arginine, R223, forms extensive interactions with the
Nrp2 binding pocket. The gaunidinium of VEGF-C R223 forms a salt-bridge with
the Nrp2-b1 L5 loop residue D323. Additionally, the aliphatic portion of the R223
side chain displays extensive van der Waals interactions with two tyrosine residues
of Nrp2-b1 that demarcate the sides of the binding pocket, Y299 (L1 loop) and
Y356 (L3 loop). In addition to interactions mediated by VEGF-C R223, there is a
hydrogen bond between the backbone carbonyl of I221 and the aromatic hydroxyl
of Nrp2 Y299.
While protein-protein binding is primarily mediated by direct interactions
between polypeptide chains, interfacing solvent also plays a critical role in
stabilizing protein-protein complexes (Janin, 1999; Karplus and Faerman, 1994).
Three water molecules, two of which bridge the interaction between VEGF-C and
Nrp2, are observed in the binding site. One solvent molecule facilitates a watermediated hydrogen bond between the side chain hydroxyl of Nrp2 T319, located
at the base of the binding pocket, and the side chain gaunidinium of VEGF-C R223
(Figure 5.2, B). Likewise, a second solvent molecule bridges the side chain
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carboxylate of Nrp2 E351 and the free carboxylate of VEGF-C. These solventmediated interactions appear to further stabilize the position of the VEGF-C Cterminus within the Nrp2-b1 binding pocket.
To confirm the critical role of the VEGF-C C-terminus we mutated the Cterminal arginine of VEGF-C to glutamate (R223E) and compared the ability of
alkaline phosphatase (AP)-tagged VEGF-C and VEGF-C R223E to bind Nrp2b1b2 affinity plates (Figure 5.2, C). Robust binding was observed between APVEGF-C and Nrp2-b1b2 but R223E binding was reduced by >95%. These data
demonstrate that the C-terminal arginine of mature VEGF-C is necessary for highaffinity Nrp2-b1b2 binding, and confirm the importance of C-terminal propeptide
processing within VEGF-C to produce a C-terminal arginine that allows avid
engagement of Nrp2.
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Figure 5.2: Mechanism of VEGF-C binding to Nrp2.
(A) Zoom of the intermolecular interface between Nrp2 (blue) and VEGF-C (green)
with the 2Fo-Fc electron density map for VEGF-C contoured at 1.0σ. Interfacing
water is shown as grey spheres. (B) Ligplot+ generated representation of the
interaction between VEGF-C (green) and Nrp2 (blue). Bond distances (Å) are
labeled in black and water is shown as grey spheres. (C) Nrp2 binding was
compared between VEGF-C and VEGF-C R223E. Binding was analyzed in
triplicate for each construct and the data is plotted as the mean ± standard
deviation.
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Occluding the Nrp2 interloop cleft abolishes binding
The structure of VEGF-C in complex with Nrp2 reveals a critical role for the
Nrp2-b1 interloop cleft, which forms the VEGF-C binding pocket. To confirm that
the Nrp2 binding pocket is responsible for VEGF-C binding, we carried out sitedirected mutagenesis against Nrp2-b1b2 to generate a construct with an occluded
binding pocket. Specifically, the residue at the base of the Nrp2-b1 interloop cleft,
T319, was mutated to arginine (Nrp2-T319R). We determined the crystal structure
of Nrp2-T319R to a resolution of 2.4 Å (Figure 5.3, A, Table 1). The R319 sidechain showed clear electron density extending into the interloop cleft between the
two binding pocket tyrosines, Y299 and Y356 (Figure 5.3, B). Superposing the
VEGF-C/Nrp2 complex onto Nrp2-T319R demonstrates that the binding site
occupied by VEGF-C is occluded in the Nrp2 mutant (Figure 5.3, C). The Nrp2T319R mutant was then used to analyze the contribution of the interloop cleft to
VEGF-C binding. We compared the binding of VEGF-C to Nrp2-b1b2 and Nrp2T319R (Figure 5.3, D). While robust binding was observed between AP-VEGF-C
and Nrp2-b1b2, binding to Nrp2-T319R was completely abolished. These data
confirm that the interloop cleft, formed by the Nrp2-b1 coagulation factor loops,
forms a structure that uniquely accommodates the C-terminus of VEGF-C to
mediate binding of the C-terminally processed ligand.
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Figure 5.3: Crystal structure and VEGF-C binding properties of Nrp2-T319R.
(A) Structure of Nrp2-T319R with the stick representation for T319R shown in red.
(B) Zoom of the Nrp2-T319R binding pocket. The blue mesh illustrates the 2Fo-Fc
electron density map for R319 contoured at 1.0σ. (C) Superimposition of VEGF-C
(green) onto the structure of Nrp2-T319R demonstrates that the binding pocket
normally occupied by VEGF-C is blocked in the mutant. (D) VEGF-C binding was
compared between Nrp2-b1b2 and Nrp2-T319R. Binding was analyzed in triplicate
for each construct and the data is plotted as the mean ± standard deviation.
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A dimeric soluble Nrp2 splice form
Based on the specific binding of VEGF-C to the Nrp2 b1 domain, we
hypothesized that the previously identified splice form of Nrp2, s9Nrp2, could
function as a selective inhibitor of VEGF-C. s9Nrp2 is an alternative Nrp2 splice
form that arises from intron inclusion in the b2 domain. An in-frame stop-codon
encoded within the intron is predicted to result in termination of translation prior to
the transmembrane domain, and thus production of a secreted Nrp2 receptor.
Given that the b1 domain of Nrp2 is solely responsible for VEGF-C binding, we
hypothesized that s9Nrp2 may be able to effectively sequester VEGF-C, thereby
functioning as an inhibitor. However, it is unknown whether the s 9Nrp2 transcript
produces a functional protein, since s9Nrp2 retains residues coding only a portion
of the b2 domain (114 of 159 residues). Indeed, s9Nrp2 lacks the coding region for
three of the eight core β-strands that normally integrate to form the distorted jellyroll fold that typifies the b1 and b2 domains of Nrp. Additionally, it was unknown
whether s9Nrp2 could accommodate the loss of the b2 C-terminal capping cysteine
and the introduction of an alternative cysteine encoded by the intronic sequence.
To investigate the physical and functional activity of s9Nrp2, we expressed and
purified the coagulation factor domain residues of s9Nrp2 (Figure 5.4, A, s9Nrp2B:
residues 275-547, plus the unique intron encoded sequence VGCSWRPL).
Analysis of s9Nrp2B by reducing SDS-PAGE revealed that purified s9Nrp2B, while
running with a larger apparent MW than Nrp2-b1 alone, was smaller than expected
from its primary sequence (Figure 5.4, B, observed MW = 22 kDa, expected MW
= 34 kDa).

Mass spectrometry confirmed that s9Nrp2B is an essentially
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homogeneous single species with MW = 22,775 Da ± 20 Da. These data, together
with the observed intact N-terminal His-tag, indicate that s9Nrp2B is cleaved Cterminal to E457 (predicted MW = 22,792 Da). Thus, the proteolyzed s 9Nrp2B
contains only a single cysteine residue from the b2 domain (C434), which normally
forms an intradomain disulfide. Surprisingly, under non-reducing conditions,
s9Nrp2B ran with an apparent MW = 38 kDa, indicating the formation of a disulfidelinked intermolecular dimer via the free b2 domain cysteine (Figure 5.4, B). The
difference in oligomeric state was evident from size exclusion chromatography
(SEC) (Figure 5.4, C). Nrp2-b1 eluted off SEC with an apparent MW = 16 kDa
(grey line), while s9Nrp2B had an apparent MW = 38 kDa (black line), consistent
with the SDS-PAGE analysis.
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Figure 5.4: s9Nrp2B unexpectedly forms a disulfide-linked dimer.
(A) Domain organization of Nrp2 and the protein fragment utilized for our studies,
s9Nrp2B. (B) Non-reducing and reducing SDS-PAGE analysis of Nrp2-b1 and
s9Nrp2B. (C) The oligomeric state of s9Nrp2B (black line) was analyzed by sizeexclusion chromatography. Nrp2-b1 was run as a reference (grey line).
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s9Nrp2B is a uniquely potent inhibitor of VEGF-C/Nrp2 binding
To understand the structural arrangement of the s9Nrp2B dimer, we
determined the crystal structure of s9Nrp2B to a resolution of 2.4 Å (Figure 5.5, A,
Table 5.1). Continuous electron density was observed from F275 through S453,
consistent with the mass spectrometry defined C-terminus. A single dimer was
present in the asymmetric unit, with the base of each b1 domain apposed to the
other, thus forming an extended anti-parallel dimer. The orientation of the dimer is
stabilized by both the intermolecular disulfide and, unexpectedly, a unique dimeric
helical bundle formed by residues from the b1-b2 linker and b2 domain (Figure 5.5,
B). The residues that form this unique helix (residues 428-453) display dramatic
structural reorganization relative to that observed in the intact b2-domain where
they form an extended sheet and loop motif (Figure 5.5, C). The C-terminal helix
runs approximately 20° off parallel from the base of the b1 domain, an angle that
is maintained by a cluster of hydrophobic residues at the hinge region between the
helix and domain b1. The helix both caps the b1 domain and mediates the
intermolecular interaction interface with the other monomer of the s9Nrp2B dimer.
The intermolecular interface is composed of both helix-helix interactions, which are
mostly hydrophobic in nature (Figure 5B), and helix-b1 interactions, which are
mostly hydrophilic in nature.
The two binding pockets within the s9Nrp2B dimer are positioned 71 Å apart,
suggesting that it could simultaneously engage both subunits of the VEGF-C
dimer, which is 68 Å wide (Leppanen et al., 2010). Thus, we hypothesized that co-
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engagement of both VEGF-C monomers by s9Nrp2B would allow the dimer to
function as a uniquely potent inhibitor of VEGF-C/Nrp2 binding. To test this
hypothesis, we compared the inhibitory potency of ATWLPPR, an optimized
peptide inhibitor of Nrp that functions by competitive binding (Parker and Vander
Kooi, 2014; Starzec et al., 2007), with Nrp2-b1 and s9Nrp2B, both of which function
as soluble competitors through sequestration of VEGF-C (Figure 5.5, D).
ATWLPPR showed dose dependent inhibition of VEGF-C binding to Nrp2 with an
IC50 = 10 M (black line), consistent with its modest reported potency. Next, we
examined the ability of Nrp2-b1 to inhibit binding (grey line). Nrp2-b1 sequestered
VEGF-C with improved potency compared to the peptide inhibitor, with an IC 50 =
1.5 M. As expected for a monomeric competitive inhibitor, the Hill slope was
approximately -1 (ATWLPPR = -1.08 and Nrp2-b1 = -0.97). These data are
consistent with independent engagement of each VEGF-C monomer by a single
Nrp2-b1. Next, we measured the inhibitory potency of s 9Nrp2B (orange line).
Strikingly, s9Nrp2B potently sequestered VEGF-C with an IC50 = 250 nM, a
significant improvement in potency from both the peptide inhibitor and Nrp2-b1.
Additionally, the Hill slope for s9Nrp2B was -1.5. Thus, the enhanced potency of
s9Nrp2B is due to its ability to synergistically sequester the VEGF-C dimer through
simultaneous and cooperative engagement of the two VEGF-C monomers. These
data demonstrate that s9Nrp2B is a potent inhibitor of VEGF-C and represents an
exciting avenue for production of a lymphangiogenic inhibitor
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Figure 5.5: Crystal structure and inhibitory properties of s9Nrp2B.
(A) Crystal structure of the s9Nrp2B dimer (Chain A: light orange; Chain B: dark
orange). The Nrp2-b1 binding pockets are labeled with black arrows. (B) Zoom of
the dimeric helical bundle with the 2Fo-Fc electron density map contoured at 1σ.
(C) The residues of the Nrp2 b1-b2 linker and b2 domain show a dramatic
structural reorganization from an extended loop in the b1b2 sequence (blue) to an
extended helix in the s9Nrp2B dimer (orange). (D) The inhibitory potency of
ATWLPPR, Nrp2-b1, and s9Nrp2B against blocking VEGF-C/Nrp2 binding was
50]

measured. ATWLPPR inhibited binding with an IC50
0.03), Nrp2-b1 inhibited binding with an IC50

50]

= -4.98 ±

= -5.82 ± 0.09),

and s9Nrp2B inhibited binding with an IC50 = 250 nM (log[IC50] = -6.60 ± 0.08).
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Inhibition was measured in triplicate and the data is plotted as the mean ± standard
deviation.
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DISCUSSION
Structural characterization of the mechanism for VEGF-C binding to Nrp2
represents an important step for understanding the physiological and pathological
activity of VEGF-C. These data also inform the rationale design of specific VEGFC/D antagonists, including s9Nrp2B, which potently inhibits VEGF-C/Nrp2 binding
and represents a potential therapeutic avenue. Collectively, these results have
important implications for interpreting both the aberrant loss and gain of function
in the VEGF-C/Nrp2 signaling axis that critically underlies a number of disease
states.
With complementary biochemical and structural approaches we show that
VEGF-C C-terminal proteolysis is required for Nrp2 binding. The requirement for
proteolytic processing is determined by the position of the Nrp2 C-wall, formed by
the L3 coagulation factor loop residues, which specifically engages the VEGF-C
free carboxy-terminus, precluding binding of unprocessed protein. These results
provide critical insight for interpreting the altered in vitro and in vivo functionality of
alternative VEGF-C forms. While both N- and C-terminal processing regulate
VEGF-C activity (Joukov et al., 1997; McColl et al., 2003), processing at these
sites is not functionally equivalent. Indeed, loss of C-terminal processing is
uniquely detrimental, fully ablating VEGF-C function in vivo (Khatib et al., 2010),
which we demonstrate blocks Nrp2 binding.
Determining the structural basis for VEGF-C signaling via Nrp2 informs
ongoing studies to describe the effect of signaling deficiency on human disease.
Deficient VEGF-C signaling via Nrp2 has significant implications for both primary
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and secondary lymphedema. Mutations in both VEGFR-3 (Karkkainen et al.,
2000) and VEGF-C (Gordon et al., 2013) have been demonstrated to underlie
hereditary lymphedema and Nrp2 has been identified as an additional candidate
gene (Ferrell et al., 2008; Karkkainen et al., 2001) Additionally, both VEGF-C and
Nrp2 have recently been identified as candidate genes for the development of
secondary lymphedema following surgery in breast cancer (Miaskowski et al.,
2013). The structural insights gleaned from the VEGF-C/Nrp2 complex also
provide an important molecular basis for interpreting emerging exome sequencing
data that has identified Nrp2 variants in close proximity to the ligand binding
interface. Intriguingly, a stringent examination of exome sequencing data has
reported both common and rare Nrp2 variants in human populations (Tennessen
et al., 2012). Several of these variants are located in the coagulation factor loops
of Nrp2-b1, the region to which VEGF-C binds. Specifically, there are two reported
variants in the L5 loop (N321I and L322M) that are located proximal to the critical
salt-bridge formed by D323, and two in the L3 loop (Q353H and N354K). The
structural data presented here provides a rationale for examining specific
coagulation loop variants for loss of function on both a physical and functional
level.
These results provide critical insight into the physical basis for VEGF-C
binding to its receptor, Nrp2. We demonstrate that the C-terminal residues of
VEGF-C, particularly the VEGF-C C-terminal arginine (R223), engage a binding
pocket within the Nrp2-b1 domain. Interestingly, previous studies have implicated
a non-C-terminal domain within VEGF-A that is responsible for Nrp1 binding. This
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motivates studies aimed at understanding the differences between VEGF-A and
VEGF-C engagement of their cognate receptors, Nrp1 and Nrp2, respectively.
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Table 5.1: Data collection and refinement statistics
Construct:
Nrp2-VEGF-C
Data Collection
Beamline
APS 22-ID
Wavelength
1.0000
Space group
P21
Cell dimensions (Å)
41.05, 120.81,
69.84
Cell dimensions (°)
90.0, 103.29,
90.0
Unique reflections
44,081
Completeness (%)
90.6(82.0)
Resolution (Å)
1.95(2.02-1.95)
Rmerge (%)
9.9(46.6)
Redundancy
5.1(4.2)
I/σ(I)
13.1(3.0)
Refinement
Resolution limits (Å)
20.00(1.95)
No. reflections/no. to compute Rfree
41,511/2140
R(Rfree)
21.0(24.1)
No. protein residues
632
No. solvent/ion molecules
333
RMSD Bond, Å
0.006
RMSD Angle, °
1.11
Protein geometry
Ramachandran outlier/favored (%)
0/96.7
Residues with bad bonds/angles
0/0
Rotamer outliers
0

Nrp2-T319R

s9Nrp2B

APS 22-BM
1.0000
P212121
34.90, 70.76,
122.97
90.0, 90.0, 90.0

APS 22-ID
1.0000
P21212
69.36, 91.39,
67.33
90.0, 90.0, 90.0

12,223
96.4(83.2)
2.40(2.49-2.40)
8.0(29.2)
6.8(5.9)
29.4(5.1)

16,303
94.1(79.8)
2.40(2.49-2.40)
9.9(32.7)
4.4(4.1)
12.3(3.2)

20.00(2.40)
11,490/586
20.1(25.5)
313
123
0.008
1.19

20.00(2.40)
15,439/821
21.0(26.4)
361
107
0.006
1.04

0/96.1
0/0
0

0/96.7
0/0
0

Table 5.1: Data collection and refinement statistics for Chapter 5

Copyright © Matthew W. Parker 2014
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CHAPTER 6: STRUCTURAL BASIS FOR SELECTIVE VEGF-A BINDING TO
NRP1
Introduction
Nrp1 is essential for VEGF dependent angiogenesis (rev. in (Pellet-Many et
al., 2008)). The importance of Nrp1 function in vivo is illustrated by Nrp1 null mice,
which show embryonic lethality due to cardiovascular defects (Kawasaki et al.,
1999). In angiogenesis, Nrp1 functions with the VEGFR family of receptor tyrosine
kinases. Nrp1 is necessary for high affinity ligand binding to the cell surface and
specifically promotes and stabilizes the active angiogenic signaling complex
involving VEGF-A, VEGFR-2, and Nrp1 (rev. in (Grunewald et al., 2010)).
The VEGF-A gene is encoded by nine exons. A cystine knot domain,
encoded by exons 1-5, is retained in all VEGF-A isoforms. This domain is essential
for signaling, mediating homo-dimerization, and direct interaction with VEGFR
(Keyt et al., 1996). Alternative splicing of the remaining introns produces VEGF-A
molecules with varying activity, extracellular matrix binding and diffusibility (Houck
et al., 1992). It has long been recognized that the most potent stimulator of
angiogenesis is VEGF-A164/5, named for the total number of amino acid residues
in mouse and human proteins, respectively. VEGF-A164 possesses a heparin
binding domain (HBD) encoded by exons seven and eight (Fairbrother et al., 1998;
Leung et al., 1989). It has been demonstrated that Nrp1 binds to the VEGF-A HBD
(Soker et al., 1996) via its b1 coagulation factor domain (Gu et al., 2002; Mamluk
et al., 2002; Soker et al., 1998). However, the nature and extent of the interaction
is not clear and has been the source of considerable study.
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It was initially thought that exon seven encoded residues represented the
Nrp-binding region of VEGF-A, thus explaining the significant differences in the
biological potency of different VEGF-A isoforms (Soker et al., 1998). In contrast to
VEGF-A164, VEGF-A120 differs by exclusion of exon seven. The clear biological
role of exon seven encoded residues in determining the ability of the cytokine to
activate endothelial cells has been demonstrated in situ and in vivo (Keyt et al.,
1996; Soker et al., 1997). However, subsequent studies demonstrated that the
conserved exon eight encoded C-terminus of VEGF-A controls Nrp binding. All
pro-angiogenic VEGF-A isoforms retain exon eight while an inhibitory VEGF splice
form, VEGF-A165b, replaces exon eight with exon nine encoded residues (Bates et
al., 2002). Nrp binding was isolated to the C-terminal portion of the VEGF-A HBD
and a critical role was established for exon eight encoded residues (Jia et al.,
2006). Further, Tuftsin, an immuno-stimulatory peptide mimic of VEGF-A exon
eight, was found to inhibit VEGF-A binding to Nrp1, while not affecting VEGF-A
binding to VEGFR-2 (von Wronski et al., 2006). It was further shown that Nrp
possesses a specific C-terminal arginine binding pocket located in the Nrp1-b1
domain (Vander Kooi et al., 2007). All known Nrp binding proteins and peptides
have been shown to posses a C-terminal arginine (Parker et al., 2010; Starzec et
al., 2007; Teesalu et al., 2009; Vander Kooi et al., 2007).

Indeed, it was

convincingly demonstrated that VEGF-A165 and VEGF-A121 both bind Nrp1,
although with different kinetics and affinity (Pan et al., 2007b). This has left the
physical role of exon seven in receptor binding now unclear.
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There are two Nrp genes in higher vertebrates, Nrp1 and Nrp2, which share
44% identity in their primary sequence and have the same overall domain
organization (Kolodkin et al., 1997). Although Nrp1 and Nrp2 are structurally
related, they facilitate activation of functionally distinct pathways utilizing different
members of the VEGF family. Nrp1 primarily mediates VEGF-A dependent
angiogenesis (Soker et al., 1998) whereas Nrp2 primarily mediates VEGF-C
dependent lymphangiogenesis (Xu et al., 2010). Nrps involvement in multiple
physiological processes poses the unique challenge of isolating activation events
to prevent inadvertent crosstalk. Differential ligand binding and temporal and
tissue specific expression are important regulatory mechanisms controlling Nrp
function (rev. in (Staton et al., 2007)). Differential ligand binding has been shown
to be critical for the specific binding of the VEGF family members to different
VEGFRs. For example, VEGF-A binds to VEGFR-1 and VEGFR-2, but with
approximately fifty-fold higher affinity for VEGFR-1 (Waltenberger et al., 1994).
Although VEGF binding to VEGFR has been characterized, the nature and basis
for specific ligand binding to Nrp has not been determined.
In order to elucidate the molecular basis for the potent and specific binding
of VEGF-A164 to Nrp, we have determined the structure of the VEGF-A HBD bound
to Nrp1. This structure reveals an intermolecular interface with contributions from
residues encoded by both exons seven and eight. We characterize these
interactions and show that the exon eight encoded region determines high-affinity
interaction with Nrp1.

The exon seven encoded region is found to uniquely

physically engage Nrp1 and contribute to binding. Strikingly, the exon seven
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mediated interaction is shown to determine the selective binding of VEGF-A164 to
Nrp1. These results define the unique physical mechanism underlying VEGF-A
binding to Nrp.
Results
Physical basis for VEGF-A and Nrp1 binding
To understand the basis for Nrp binding of VEGF-A, we determined the
crystal structure of the VEGF-A HBD in complex with the core ligand binding
domain of Nrp1, domain b1. There were two molecules in the asymmetric unit, with
intermolecular interactions between the VEGF-A HBD and Nrp-b1 (Figure 6.1, A,
Table 6.1). The VEGF-A HBD of Chain A fully engages the Nrp1-b1 moiety of
Chain B and reveals an extended intermolecular interaction interface between
VEGF-A and Nrp1 (gold) (Figure 6.1, B). The intermolecular interface is formed
by both exon seven (blue) and eight (green) encoded residues of the VEGF-A HBD
(Figure 6.1, B). Analysis of the HBD/Nrp1-b1 complex reveals that the interface is
predominantly hydrophilic in nature and is stabilized by a network of hydrogen
bonds and salt bridges.

The HBD retains the overall structural architecture

previously determined (Fairbrother et al., 1998), with an R.M.S.D. of 2.0Å
(overlaying residues 115-164). The orientation of the C-terminal peptide-like exon
eight encoded residues is significantly different from that observed in solution. This
unique orientation is due to the presence of an intramolecular salt-bridge formed
between D142 and R163 as well as its direct association with Nrp1 (Figure 6.1, C
& D). The Nrp1 b1 domain shows no significant differences from previously
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determined structures with a R.M.S.D. of 0.8Å (PDB=2QQI, overlaying residues
274-429).
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Figure 6.1: The crystal structure of the VEGF-A HBD in complex with Nrp1.
(A) Chain A (green) and Chain B (blue) crystallized in an anti-parallel fashion with
the Chain A VEGF-A HBD fully engaging the Nrp1-b1 domain of Chain B, and that
of Chain B engaged by the symmetry related Nrp1-b1 domain of Chain A. The
intermolecular complex enclosed in the dashed box is shown in (B) A space-filling
model revealing the specific interface with VEGF-A164 exon seven and eight (Chain
A) encoded residues with Nrp1 (Chain B). (C) A stereo view of the 2FO-FC electron
density map contoured at 1.0 sigma of Nrp1 (gold) and exon seven (blue) and eight
(green) of VEGF-A164. An intramolecular salt bridge between D142 and R163 of
VEGF-A164 and intermolecular salt-bridge between D320 of Nrp1 and R164 of
VEGF-A164 are observable. (D) A stereo view of the Fo-Fc omit electron density
map for the HBD residues contoured at 3.0 sigma
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Isoform specific binding of VEGF-A to Nrp1
Differences in potency, functionality, and receptor binding have been
reported for VEGF-A164 and VEGF-A120, which differ only in the inclusion of exon
seven in VEGF-A164. To delineate the different roles of these exons in Nrp binding,
the dose dependent binding of AP-VEGF-A164 and AP-VEGF-A120 to Nrp1 was
analyzed (Figure 6.2).

VEGF-A164 (black line) bound Nrp1 with high affinity,

Kd=3.0nM±0.2nM. As expected for high density coupling of Nrp1, the observed
binding is consistent with the reported tight cell surface binding (Soker et al., 1998).
VEGF-A120 (gray dashed line) also bound Nrp1, but with lower affinity
(Kd=22nM±1nM). These data indicate that both exon eight containing isoforms of
VEGF-A are able to bind to Nrp1, but differ in their affinity.
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Figure 6.2: VEGF-A164 binds to Nrp1 with high-affinity.
VEGF-A164 (black line) binds Nrp1 with a Kd=3.0nM±0.2nM. VEGF-A120 (gray
dashed line) binds Nrp1 with a Kd=22nM±1nM.
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Exon eight encoded residues are essential for high-affinity VEGF-A binding
to Nrp1
Close examination of the residues of exon eight that interact with Nrp1
reveals that VEGF-A164 utilizes a C-terminal arginine (R164) to bind Nrp1 (Figure
6.3, A). Analysis of the intermolecular interface in this region indicates that R164
contributes a majority of the interaction with Nrp1. While the electron density
associated with the side-chain indicates some disorder (Figure 6.1, C & D), the
binding mode is seen in both molecules in the asymmetric unit, and is very similar
to the previously determined structure with the inhibitory peptide Tuftsin (TKPR), a
peptide mimic of VEGF-A exon eight (Figure 6.3, B). R164 is fully engaged by b1,
burying 247 Å2 in the binding pocket. A salt-bridge is formed with D320 and the
free carboxy-terminus forms hydrogen bonds with S346, T349, and Y353 of the b1
domain (Figure 6.3, A).
To characterize the contribution of the exon eight encoded C-terminal
arginine to binding, we analyzed site-directed mutants of both VEGF-A and Nrp1.
To determine the role of the salt-bridge, the C-terminal arginine was first mutated
to alanine (Figure 6.3, C). Retention of R164A by Nrp1 (black bar) was reduced
by 97% relative to WT VEGF-A164. To determine the role of the carboxy-terminal
hydrogen bond network, a VEGF-A164 construct with a C-terminal di-alanine
addition was generated. Retention of R164R+AA by Nrp1 (gray bar) was reduced
by 87% relative to WT VEGF-A164. The observed contributions from both sidechain and carboxy-terminus emphasize the unique requirement for a carboxyterminal arginine in high affinity Nrp ligands.

107

Lastly, a charge reversal was

produced. R164E (red bar) showed no significant binding to Nrp1. These data
demonstrate the essential role of a carboxy-terminal arginine in VEGF.
To complement these results we examined the amount of VEGF-A164
binding retained when the Nrp1 binding pocket was occluded. T316, which sits at
the base of the Nrp1 binding pocket adjacent to D320 (Figure 6.3, D), was mutated
to arginine to generate a binding-deficient Nrp1 mutant. The binding of AP-Nrp1
or AP-T316R to VEGF-A164 was determined (Figure 6.3, E). Strikingly, occlusion
of the Nrp1-b1 binding pocket in AP-T316R completely abolished binding with
VEGF-A164. These data demonstrate the essential role of the Nrp1-b1 C-terminal
arginine binding pocket in mediating high-affinity VEGF-A binding.
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Figure 6.3: The exon eight encoded C-terminal arginine of VEGF-A
mediates high-affinity Nrp1 binding.
(A) R164 forms specific contacts with the b1 binding pocket of Nrp1. The
guanidinium moiety forms a salt-bridge with D320 carboxylate oxygen’s (dashed
red lines, 3.08Å and 3.32Å). The carboxy-terminus forms hydrogen bonds with
three Nrp1-b1 residues (dashed gray lines, 3.08Å, 2.95Å, and 3.13Å to S346,
T349, and Y353, respectively). (B) Tuftsin binds to the Nrp1-b1 domain
(PDB=2ORZ) utilizing the same C-terminal arginine binding mode. (C)
Mutagenesis demonstrates a specific role for the side chain (R164A, black bar)
and carboxy-terminus (R164R+AA, gray bar) in Nrp1 binding. Charge reversal
(R164E, red bar) completely abolishes binding to Nrp1. Statistical comparison of
mean wild-type and mutant binding demonstrates significant differences,
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p<0.0002, between all constructs. AP tagged wild-type and mutant VEGF was
used at an activity of 25 μmole p-NPP hydrolyzed/min/μL. (D) A surface
representation of VEGF-A bound to Nrp1 reveals the critical location of T316 (red)
and illustrates the mechanism by which mutation to arginine would occlude
binding. (E) Occlusion of the Nrp1 binding pocket in the Thr-Arg Nrp1 mutant
(T316R, red bar) completely abolishes binding to VEGF-A164. AP-tagged wild-type
and mutant Nrp1 was used at an activity of 1 μmole p-NPP hydrolyzed/min/μL.
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Exon seven residues directly physically engage the L1 loop of Nrp1
The enhanced affinity of VEGF-A164 for Nrp1 versus that of VEGF-A120
suggests a role for the exon seven encoded residues in the interaction with Nrp1.
The reported structure reveals that specific exon seven encoded residues also
directly engage Nrp1. The interface with exon seven encoded residues is more
extended and involves K146, E151, and E154. The residue with the largest
interface contribution is E154, with 67 Å2 buried surface area at the interface. The
side chain of E154 forms a hydrogen bond with both the backbone amide and sidechain hydroxyl of T299 in the Nrp1 L1 loop (Figure 6.4, A). The role of E154 in Nrp
binding was examined (Figure 6.4, B). An E154A (purple bar) mutant showed
reduced Nrp1 binding, but the reduction was not as pronounced as that observed
for R164 mutants.
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Figure 6.4: E154 of VEGF-A164 exon seven contributes to Nrp1 binding.
(A) E154 interacts with the side chain hydroxyl (bond distance=2.73Å) and
backbone amide (bond distance=3.16Å) of T299 of the Nrp1 L1 loop. (B) Mutation
of E154 to alanine (E154A, purple bar) reduces binding to Nrp1 (p<0.0004). AP
tagged wild-type and mutant VEGF was used at an activity of 25 μmole p-NPP
hydrolyzed/min/μL.
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Selective VEGF-A binding to Nrp1
Nrp1 and Nrp2 b1 domains are structurally highly homologous (Figure 6.5,
A). However, there are regions that are divergent. The L1 loops of Nrp1 and Nrp2
have distinct amino acid composition: the Nrp1 L1 loop T299 is replaced by D301
in the Nrp2 L1 loop. This replacement would be expected to result in electrostatic
repulsion of E154 of VEGF-A164. We generated a Nrp1 L1 loop chimeric mutant,
replacing the L1 loop of Nrp1 (299-TN-300) with the Nrp2 loop (301-DGR-303),
and assessed its ability to bind VEGF-A164 (Figure 6.5, B). This mutant shows a
75% reduction in its ability to bind VEGF-A164 (gold/cyan bar) relative to WT Nrp1
(gold bar). These data directly demonstrate that the VEGF-A164 E154 interaction
with the L1 loop of Nrp1 contributes to binding.
As observed, substitution of the L1 loop of Nrp2 into Nrp1 dramatically
reduces Nrp1 binding to VEGF-A164. This led us to consider whether the physical
interaction we describe may be directly reflected in decreased affinity of VEGFA164 for Nrp2. To test this, we assayed the binding of VEGF-A164 to Nrp2. In fact,
VEGF-A164 shows dramatically weaker binding to Nrp2, with approximately fiftyfold lower affinity (Figure 6.5, C, black line, Kd=150nM±4nM) relative to Nrp1
(Figure 6.2, black line, Kd=3nM). Our data suggests that the observed binding
selectivity may be due to the exon seven encoded residues. To test this, we
compared the binding of VEGF-A120 to the two Nrp receptors. Indeed, binding of
VEGF-A120 to Nrp2 is unchanged (Figure 6.5, C, gray dashed line, Kd=23nM±1nM)
from that of Nrp1 (Figure 6.2, gray dashed line, Kd=22nM).
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To confirm that the observed binding selectivity involves electrostatic
repulsion between E154 and Nrp2, we tested the binding of E154A to Nrp2 (Figure
6.5, D). Indeed, E154A (purple bar) shows three-fold higher retention by Nrp2
relative to WT VEGF-A164 (blue).

114

A.

B.

100

Retained AP-Nrp1 Activity
(% of WT Nrp1)

L1
Nrp1: YST-NWS
Cons: YS
W+
Nrp2: YSDGRWT

Nrp1
TN-DGR

75

50

25

0

D.

VEGF-A164
VEGF-A120

20

Retained AP-VEGF-A164 Activity
(% of WT VEGF-A164)

Retained AP-VEGF-A Activity
(µmole p-NPP hydrolyzed/min/µL)

C.

25

15

10

5

0
0

1

2

3

4

5

6

7

8

9

10

11

400

VEGF-A164
300

E154A

200

100

0

[VEGF-A] (nM)

Figure 6.5: Exon seven encoded residues of VEGF-A164 are responsible for
Nrp1 binding selectivity.
(A) Superimposition of Nrp1 (PDB=1KEX) and Nrp2 b1 domains (PDB=2QQJ,
residues 276-427) reveals a similar overall architecture, R.M.S.D.=0.7Å, but
unique amino acid composition of the L1 loop, with Nrp1-T299 and Nrp2-D301
highlighted in gold and cyan, respectively. (B) Chimeric Nrp1, containing the L1
loop of Nrp2 (gold/cyan), loses over 75% binding to VEGF-A164 relative to WT Nrp1
(gold) (p<0.000004). AP-tagged wild-type and mutant Nrp1 was used at an activity
of 1 μmole p-NPP hydrolyzed/min/μL. (C) VEGF-A120, which lacks exon seven, has
essentially the same affinity for Nrp2 (gray dashed line, Kd=23nM±1nM) as it does
for Nrp1. VEGF-A164 retains exon seven and has dramatically reduced affinity for
Nrp2 (black line, Kd=150nM±4nM) compared to Nrp1. (D) Nrp2 shows three-fold
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higher retention of E154A (purple bar) relative to WT VEGF-A164 (blue bar)
(p<0.0003). AP tagged wild-type and mutant VEGF was used at an activity of 25
μmole p-NPP hydrolyzed/min/μL.
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Discussion
Together, these data demonstrate a mechanism for selective VEGF binding
to Nrp. We report the first detailed picture of the structural basis for the binding of
Nrp1 and VEGF-A. The interface is shown to involve regions encoded by both
exons seven and eight and is found to determine splice-form specific receptor
binding and selectivity (Figure 6). Together with mutagenesis of key interfacial
residues, our data define the specific contribution of different regions of VEGF-A.
The exon eight encoded C-terminus of VEGF-A is confirmed to be necessary for
high-affinity Nrp binding. The C-terminal arginine of VEGF-A is shown to engage
the Nrp1-b1 domain binding pocket utilized by all known ligands (Parker et al.,
2010; Starzec et al., 2007; Teesalu et al., 2009; Vander Kooi et al., 2007). A
number of mutations to residues in the C-terminal arginine binding pocket have
been reported (Herzog et al., 2011). These mutations modulate binding to Nrp1
and show different signaling properties. We report here that T316R represents a
true binding-deficient Nrp1 mutant that will be useful for future studies.
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Figure 6.6: The HBD of VEGF-A is responsible for selective binding to the
Nrp1 b1 domain.
Exon eight encoded residues mediate high-affinity binding whereas exon seven
encoded residues primarily govern selectivity.
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Exon seven encoded residues are also found to directly physically interact
with Nrp1. In particular, we show that E154 directly physically engages T299 in
the L1 loop of Nrp1, resulting in enhanced and selective Nrp1 binding. The
importance of this interaction interface is further underlined by the recently
reported VEGF blocking antibody, Anti-Nrp1B (Liang et al., 2007). Surprisingly,
this antibody was shown not to block the expected C-terminal arginine binding site
of the b1 domain. Instead it binds to residues in the nearby loops including T299
of the Nrp1 L1 loop (Appleton et al., 2007). These data reveal that Anti-Nrp1B
engages a binding site on Nrp1 that is shared with VEGF-A164, thus explaining its
ability to potently inhibit VEGF-A binding to Nrp1.
It is interesting to note that the other VEGF family members that signal via
Nrp1 also possess conserved electronegative residues at positions analogous to
E154: D158 in VEGF-B167 and E194 in placental growth factor 3 (PlGF) isoform-3.
This suggests that electrostatic repulsion between VEGF family members and
Nrp2 may be a general mechanism governing ligand binding selectivity.
While the Nrp2 L1 loop chimera resulted in increased VEGF-A164 binding
(data not shown), the observed binding is still significantly lower than that observed
for wild-type Nrp1. Consistent with this observation, mutating R287 and N290 of
Nrp2, which are immediately N-terminal to the L1 loop, has been reported to
enhance the binding of VEGF-A to Nrp2 (Geretti et al., 2007). Since the L1 loop
of Nrp2 is highly conserved, it will also be interesting to explore if there are distinct
mechanisms that promote selective Nrp2 binding by its in vivo ligands VEGF-C
and VEGF-D.

Indeed, there may be Nrp-dependent physical mechanisms
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differentiating

Nrp1

dependent

angiogenesis

and

Nrp2

dependent

lymphangiogenesis. This also suggests that design of specific Nrp inhibitors that
exploit the difference in the L1 loop may be attainable.
The current Chapter and Chapter 6 have focused on understanding the
mechanism of Nrp binding to the VEGF family of ligands. Earlier Chapters
(Chapters 3-4) have provided the molecular basis for Sema/Nrp binding. We have
found both distinct and overlapping mechanisms that facilitate differential ligand
binding to the Nrp family. These data led us to consider how inhibitory modalities
could be designed to selectively inhibit one family of ligands over another.
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Table 6.1: Data collection and refinement statistics
Data Collection
Beamline
APS 22-ID
Wavelength
1.0000
Space group
P43
Unit cell parameters (a, b, c)
114.97, 114.97, 50.94
Unique reflections
18014
Completeness (%)
91.5(55.4)
Resolution (Å)
2.65(2.74-2.65)
Rmerge (%)
12.2(53.9)
Redundancy
4.3(1.7)
I/σ(I)
11.4(2.02)
Refinement
Resolution limits (Å)
20.0(2.65)
No. reflections/no. to compute Rfree
17074/916
R(Rfree)
21.2(26.7)
No. protein residues
432
No. solvent/ion molecules
19
No. phosphate molecules
1
RMSD Bond, Å
0.005
RMSD Angle, °
1.01
Ramachandran outlier/favored (%)
0/96
Residues with bad bonds/angles (%)
0/0
Rotamer outliers (%)
0.26

Table 6.1: Data collection and refinement statistics for Chapter 6

Reprinted in full or part with permission from: Structural Basis for Selective
Vascular Endothelial Growth Factor-A (VEGF-A) Binding to Neuropilin-1.
Matthew W. Parker, Ping Xu, Xiaobo Li, and Craig W. Vander Kooi, Journal of
Biological Chemistry 2012 287, 11082-11089. Copyright 2013 ASBMB.
Copyright © Matthew W. Parker 2014
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CHAPTER 7: MECHANISM OF SELECTIVE VEGF-A BINDING BY NRP1
REVEALS A BASIS FOR SPECIFIC LIGAND INHIBITION
Introduction
The Nrp family of receptors coordinate ligand-binding events that mediate
endothelial cell migration and proliferation and neuronal chemorepulsion (reviewed
in (Zachary et al., 2009)). There are two Nrp homologues, Nrp1 and Nrp2, which
share the same overall domain architecture with 44% identity in their primary
sequence.

Nrp ligands include the VEGF family of pro-angiogenic cytokines

(Soker et al., 1998) and the Sema3 family (He and Tessier-Lavigne, 1997;
Kolodkin et al., 1997) of axon guidance molecules (Nakamura et al., 1998). Both
VEGF and Sema3 family of ligands are composed of multiple genes, splice forms,
and proteolytic products with different receptor binding specificity and physiological
function.
Soluble receptors capable of sequestering specific ligands are an attractive
modality for blocking ligand-dependent signaling pathways. VEGF-Trap, a soluble
chimera of VEGFR, containing the domains necessary for ligand binding (Holash
et al., 2002), has been approved for use as a clinical agent blocking VEGF-A
dependent angiogenesis (Stewart et al., 2012). The identification of endogenously
expressed soluble Nrp receptors (sNrp) with anti-tumor activity (Gagnon et al.,
2000) has prompted interest in the use of engineered Nrp molecules as specific
pathway inhibitors. It was recently reported that mutation to the Nrp2-b1 domain
enhances its ability to bind VEGF-A (Geretti et al., 2007) and that administration
of this truncated receptor effectively antagonizes VEGF-A dependent angiogenic
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signaling (Geretti et al., 2010). A Sema3 specific inhibitor would be of significant
utility. While Sema3 mediated repulsive cues are essential during development,
they pose a significant barrier to axonal regrowth following injury (de Wit and
Verhaagen, 2003). This is particularly the case in repair following spinal cord
injury. In response to spinal cord injury a glial scar forms that serves as a barrier
to regenerating axons. Sema3 family members are produced by meningeal cells
located in the glial scar and are a major component of the repulsive cues that
prevent axonal regeneration (De Winter et al., 2002; Niclou et al., 2003). Blocking
inhibitory cues represents one fundamental mode of regenerative therapy for
partial cord injuries (Fawcett, 2006). However, due to limited understanding of the
determinants of Nrp binding specificity, no soluble Nrp-trap exists that is specific
for Sema3.
The conserved Nrp architecture provides Nrp homologues with the ability to
bind ligands using a common binding mode. As demonstrated in Chapters 5 and
6, the b1 coagulation factor domain of Nrp1 and Nrp2 contains a conserved cleft
optimally suited for binding a C-terminal arginine that is necessary for ligand
binding (Parker et al., 2012c; Starzec et al., 2007; Vander Kooi et al., 2007). All
VEGF family members contain a C-terminal arginine. Additionally, in Chapters 3
and 4 we demonstrated that all Sema3 family members contain at least one
conserved furin recognition sequence that is endogenously cleaved to liberate a
C-terminal arginine (Adams et al., 1997; Parker et al., 2010). Indeed, binding to
this shared site underlies the observed competition between VEGF and Sema3
(Geretti et al., 2007; Parker et al., 2010).
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In physiological context, physical and functional specificity is observed
between receptor-ligand pairs. Nrp1 acts as the functional receptor for VEGF-A
(Soker et al., 1998) and Sema3A (He and Tessier-Lavigne, 1997; Kolodkin et al.,
1997) and Nrp2 acts as the functional receptor for VEGF-C (Karkkainen et al.,
2001) and Sema3F (Giger et al., 1998). The mechanism underlying specific
Sema3 family member binding by Nrp1 and Nrp2 has been shown to involve dualsite binding. The Nrp b1 domain binding to the Sema3 C-terminal domain is
necessary for high-affinity binding but does not display specificity for Nrp1 or Nrp2
(Giger et al., 1998; Parker et al., 2010). Secondarily, the N-terminal a1 domain of
Nrp1 and Nrp2 selectively binds the sema domain of different Sema3 family
members (Chen et al., 1998; Koppel et al., 1997; Merte et al., 2010). Indeed, a
Sema3 binding-deficient Nrp has been reported which disrupts the unique a1/sema
interaction (Gu et al., 2002). However, since there is no known secondary binding
site, the basis for specificity in VEGF binding remains unclear.
It was recently demonstrated that the essential VEGF-A164/165 (VEGF-A)
isoform binds preferentially to Nrp1 (Parker et al., 2012c). The C-terminal arginine
binding cleft of the Nrp1-b1 domain is formed by three loops which are a common
feature among coagulation factor domains. While the cleft is conserved, a
significant number of residues surrounding this binding pocket differ between Nrp1
and Nrp2 and may contribute to the observed ligand binding specificity. Indeed,
the L1 loop of the Nrp b1 domain has been shown to contribute to the observed
preferential binding of VEGF-A to Nrp1 (Parker et al., 2012c). However, this
interaction alone is insufficient to explain the marked difference in potency of
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VEGF-A binding to Nrp1 and Nrp2, therefore other molecular determinants of this
preferential binding must exist. The recently reported Nrp2 mutation, when Nrp2
R287 is replaced with the corresponding Nrp1 E285, shows enhanced VEGF-A
binding and, importantly, unchanged binding to Sema3F (Geretti et al., 2007).
Together, these data suggest that the Nrp b1 domain contains distinct features
that govern specific ligand binding and could be exploited to produce specific
inhibitors of Nrp ligands. By understanding how selective VEGF binding is
achieved, and whether these regions also affect Sema3 binding, a Nrp molecule
that specifically bound Sema3 and blocked Sema3 repulsive cues could be
designed as a potentially important therapeutic tool.
In the present study we determined the basis for preferential Nrp1 binding
to VEGF-A. Mutagenesis of residues surrounding the shared C-terminal arginine
binding pocket identifies residues that differ between Nrp1 and Nrp2 and underlie
the observed VEGF-A specificity. A chimeric Nrp2, which combines the identified
mutations, is capable of binding VEGF-A similarly to Nrp1 whereas a chimeric Nrp1
shows significant loss of VEGF-A binding. We further show that Nrp1 and Nrp2
both bind Sema3F with similar affinity and that both Nrp2 and the chimeric Nrp1
can selectively sequester Sema3. These data establish that unique mechanisms
are used by Sema3 and VEGF-A to mediate specific Nrp binding, revealing a basis
for the use of engineered Nrp molecules as selective inhibitors of Sema3.
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Results
Soluble Nrp1 selectively inhibits VEGF-A
To assay the inhibitory potency of Nrp1 and Nrp2, we tested the ability of
Nrp1 and Nrp2 to inhibit VEGF-A binding to Nrp1 affinity plates in a dose
dependent manner (Figure 7.1). Nrp1 was able to potently inhibit the binding of
VEGF-A to Nrp1 affinity plates with an IC50 = 1.8 μM (log IC50 = -5.7 ± 0.2) (black
line, Figure 7.1). In contrast, Nrp2 was able to inhibit binding only at the highest
concentrations with an IC50≈ 310 μM (log IC50 = -3.5 ± 0.4) (grey line, Figure 7.1).
Each experiment was performed in triplicate with unique protein preparations to
provide a direct measurement of inter-assay variability, with 11% inter-assay
variability observed for Nrp1 compared to 3.5% intra-assay variability. These data
demonstrate, both qualitatively and quantitatively, the robust quality and
reproducibility of the reported data. The greater than 100-fold difference in IC50
between Nrp1 and Nrp2 is consistent with the previously reported VEGF binding
selectivity (Parker et al., 2012c).
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Figure 7.1: Nrp1 selectively inhibits VEGF-A binding.
The ability of Nrp1 and Nrp2 to selectively sequester AP-VEGF-A from Nrp1
adsorbed on affinity plates was assessed. The amount of retained AP-VEGF-A
was measured and the Nrp concentration recorded where half-inhibition was
achieved. Nrp1 inhibited the binding of VEGF-A with an IC50 = 1.8 μM (black line).
Inhibition by Nrp2 was seen only at the highest concentration of protein attainable
with an estimated IC50 ≈ 310 μM (grey line). Experiments were performed in
triplicate and reported as the mean ± 1 S.D.
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Identification of the regions of Nrp1 that confer selective VEGF-A binding
The selective ability of Nrp1 to inhibit VEGF-A binding led us to consider the
mechanism of this specificity. The predominant Nrp structural determinants
mediating VEGF-A binding have been localized to domain b1 (Geretti et al., 2007;
Gu et al., 2002; Parker et al., 2012c). The b1 domains of Nrp1 and Nrp2 are 45%
identical. Conserved between both are the residues which form the C-terminal
arginine binding pocket demonstrated to be essential for VEGF-A/Nrp binding
(Vander Kooi et al., 2007) (Figure 7.2, A, asterisk). Alignment of Nrp1 and Nrp2
domain b1 reveals diversity in the primary sequence conservation of regions
surrounding the binding pocket. There are three different categories of residues:
those that are well conserved in both Nrp1 and Nrp2, those that are not well
conserved, and those which are distinct between Nrp1 and Nrp2 but well
conserved within each ortholog. We hypothesized that residues in this last
category likely underlie the observed specific Nrp1/VEGF-A binding. Further,
residues nearby the binding pocket, especially those in the coagulation-factor
loops (L1-L3) often utilized in ligand binding in coagulation-factor domain proteins
(Fuentes-Prior et al., 2002), most likely underlie specific binding.
Based on these two criteria, i.e., that residues are separately conserved
within Nrp1 and Nrp2 and that they are nearby the binding site, four regions were
selected:

Nrp1:E285/Nrp2:R287,

Nrp1:299-TN-300/Nrp2:301-DGR-303,

Nrp1:304-ER-305/Nrp2:307-QQ-308, and Nrp1:350-KKK-352/Nrp2:353-QNG-355
(Figure 7.2, B). Mutant proteins were produced by swapping the selected
sequences between the two Nrp homologues. Nrp residues that contribute to the
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observed specificity would be expected to reduce Nrp1 binding and enhance Nrp2
binding when reversed. These chimeric Nrp molecules were expressed with an Nterminal AP tag. The binding of AP-Nrp constructs to VEGF-A affinity plates was
measured and normalized relative to wild-type Nrp1 or Nrp2 binding. Reduced
binding to VEGF-A was observed for all Nrp1 chimeras relative to wild-type Nrp1
(Figure 7.2, C), suggesting a role of these sequences in VEGF-A binding. Three
of the four Nrp2 chimeras showed enhanced affinity for VEGF-A relative to wildtype Nrp2 (Figure 7.2, D). The reduction in VEGF-A binding for both Nrp1 ER/QQ
and Nrp2 QQ/ER suggests that these mutations may destabilize the protein and
this mutation was therefore excluded from further study. These results suggest that
E285, 299-TN-300, and 350-KKK-352 of the Nrp1-b1 domain contribute to
selective VEGF-A binding.
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Figure 7.2: Nrp1 residues mediate specific VEGF-A binding.
(A) Alignment of orthologous Nrp1 and Nrp2 b1 domains shows conservation of
residues critical for C-terminal arginine binding (marked with a *) but variability
within regions surrounding the interloop cleft (orange: Nrp1:E285/Nrp2:R287
(Geretti et al., 2007); green: Nrp1:299-TN-300/Nrp2:301-DGR-303; blue:
Nrp1:304-ER-305/Nrp2:307-QQ-308; purple: Nrp1:350-KKK-352/Nrp2:353-QNG355). Below the alignment is a conservation histogram illustrating identity across
the displayed sequences. (B) Surface representation of the Nrp b1 domain reveals
that the direct VEGF-A binding region (gold) (Parker et al., 2012c) is closely
associated with the selected regions (colored according to 2A) in threedimensional space. (C) VEGF-A binding of Nrp1 mutants reveals loss of binding
for each mutant protein compared to wild-type. Retained AP-Nrp1 binding is
reported as the percent of retained wild-type AP-Nrp1. (D) Determination of the
VEGF-A binding capacity of Nrp2 mutants reveals that three of the four Nrp2
chimeras show enhanced VEGF-A binding compared to wild-type. Retained AP-
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Nrp2 binding is reported as the percent of retained wild-type AP-Nrp2. Experiments
were performed in triplicate and reported as the mean ± 1 S.D.
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Nrp2Chimera inhibits VEGF-A binding
To assess whether the identified loops compose the predominant features
of the Nrp1-b1 domain that confer specific VEGF-A binding, we generated a Nrp1
and Nrp2 molecule which incorporated all three different mutations in a single
construct, termed Nrp1Chimera and Nrp2Chimera. To ensure that the mutant proteins
were well folded, CD was utilized to assess wild-type and chimeric constructs
(Figure 7.3, A). All proteins produce spectra consistent with the expected βsandwich architecture of the protein. Further, wild-type and mutant proteins show
superimposable spectra demonstrating that the mutations are not structurally
deleterious. As a quantitative measure of the selectivity of Nrp Chimera proteins for
VEGF-A, we assayed the potency of Nrp1Chimera and Nrp2Chimera in inhibiting APVEGF-A binding to Nrp1 affinity plates (Figure 7.3, B). The dose-dependent ability
of these constructs to inhibit VEGF-A binding was compared to wild-type Nrp1 and
Nrp2 (Figure 7.1). The Nrp1Chimera showed a significant loss in potency, with an
IC50 = 62 μM (log IC50= -4.2 ± 0.1) (blue line, Figure 7.3, B), an over 30-fold loss in
potency compared to Nrp1 (black line, Figure 7.1). Strikingly, Nrp2Chimera gained
fifty-fold potency relative to Nrp2, with an IC50 = 3.9 μM (log IC50 = -5.4 ± 0.2)
(green line, Figure 7.3, B), nearly to the level observed for wild-type Nrp1.
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Figure 7.3: NrpChimera molecules exhibit reversed VEGF-A specificity.
(A) The secondary structure of WT Nrp and NrpChimera was assessed by CD. The
overlapping spectra of NrpChimera with wild-type Nrp demonstrate that the
incorporated mutations are not structurally deleterious. (B) Nrp1 Chimera (blue line)
and Nrp2Chimera (green line) were tested for their ability to selectively sequester APVEGF-A from Nrp1 adsorbed on affinity plates. The NrpChimera molecules show
reversed VEGF-A specificity with Nrp1Chimera having a marked reduction in
inhibitory potency (IC50 = 62 μM) and Nrp2Chimera exhibiting a significant gain in
potency (IC50 = 3.9 μM). Wild-type Nrp1 (black dotted line, IC50 = 1.8 μM) and Nrp2
(grey dotted line, IC50 ≈ 310 μM) are shown for comparison (data from Figure 7.1).
Experiments were performed in triplicate and reported as the mean ± 1 S.D.
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Nrp1 and Nrp2 equivalently inhibit Sema3F binding
VEGF and Sema3 are the two major ligand families of Nrp receptors. The
Sema3 family of ligands has been demonstrated to bind Nrp receptors via a dualsite binding mechanism. The Sema3 semaphorin domain mediates specific ligand
binding via the Nrp a1 domain (Koppel et al., 1997) and the Sema3 basic Cterminus mediates common high-affinity binding to the Nrp b1b2 domains (Gu et
al., 2002). To confirm that the Nrp1 and Nrp2 b1b2 domains bind to Sema3, and
that they do not display specificity, we measured their ability to inhibit the binding
of AP-Sema3F to Nrp1. Both Nrp1 and Nrp2 showed a dose-dependent inhibition
of AP-Sema3F binding with equivalent observed potency for Nrp1, IC 50 = 2.0 μM
(log IC50 = -5.7 ± 0.1), and Nrp2, IC50 = 2.7 μM (log IC50 = -5.6 ± 0.3) (Figure 7.4,
A). To confirm that this interaction is mediated by the C-terminal domains of
Sema3, we assayed the ability of Nrp1 and Nrp2 b1b2 domains to inhibit the
binding of AP-Sema3F-Ig-basic to Nrp1. Consistent with the potency against fulllength Sema3F, Nrp1 inhibited AP-Sema3F-Ig-basic binding with an IC50 = 1.2 μM
(log IC50 = -5.9 ± 0.1) and Nrp2 inhibited AP-Sema3F-Ig-basic binding with an IC50
= 6.2 μM (log IC50 = -5.2 ± 0.2) (Figure 7.4, B).
These data demonstrate that the b1b2 domain of Nrp1 and Nrp2 contain
structural determinants capable of C-terminal Sema3F binding and that this
binding does not show specific binding to the two Nrp homologues. To confirm
that the interaction between the basic domain of Sema3F and Nrp1-b1b2 is
conserved across the Sema3 family, and that this interaction site overlaps with that
for VEGF-A, we measured the ability of a peptide corresponding to the C-terminus
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of both Sema3F and Sema3A to inhibit VEGF-A binding (Figure 7.4, C). CfurSema3F and C-furSema3A, peptides corresponding to the furin-activated forms
of Sema3F and Sema3A, respectively, were assayed for their ability to
competitively inhibit the binding of VEGF-A. Both peptides showed potent, dosedependent inhibition of AP-VEGF-A binding with IC50 = 22 nM (log IC50 = -7.7 ±
0.04) and 67 nM (log IC50 = -7.2 ± 0.04) for C-furSema3F and C-furSema3A,
respectively. These data confirm that the Sema3 family of ligands utilize their basic
C-terminus for equivalent high-affinity binding to the Nrp b1b2 domains, and that
this binding is competitive with that of VEGF-A.
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Figure 7.4: Nrp inhibits Sema3F binding through interaction with the Cterminal basic domain.
(A) Nrp1 and Nrp2 dependent inhibition of AP-Sema3F binding to Nrp1 affinity
plates was measured. Both Nrp homologues showed similar ability to compete for
AP-Sema3F, with Nrp1 inhibiting with an IC50 = 2.0 μM and Nrp2 with an IC50 =
2.7. μM. (B) The ability of Nrp1 and Nrp2 to selectively sequester AP-Sema3F-Igbasic from Nrp1 adsorbed on affinity plates was assessed. The amount of retained
AP-Sema3F-Ig-basic was measured and the Nrp concentration recorded where
half-inhibition was achieved. Nrp1 (black line) and Nrp2 (grey line) had similar
ability for inhibiting Sema3F binding with IC50 = 1.2 μM and IC50 = 6.2 μM,
respectively. (C) Two peptides corresponding to the C-terminal basic domain of
Sema3A (C-furSema3A) and Sema3F (C-furSema3F) were analyzed for their
ability to inhibit AP-VEGF-A binding to Nrp1 affinity plates. Both peptides potently
inhibited binding, with an IC50 = 22nM and 67nM for C-furSema3F and CfurSema3A, respectively. Experiments were performed in triplicate and reported
as the mean ± 1 S.D.
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Nrp2 and Nrp1Chimera relieve C-furSema mediated inhibition of AP-VEGF-A
binding to Nrp1
Nrp1 and Nrp2 display similar affinity for Sema3F (Figure 7.4, A & B) but
Nrp2 has markedly reduced binding to VEGF-A relative to Nrp1 (Figure 7.1). This
data suggests that Nrp2 may be a potent and specific inhibitor of Sema3 binding
to Nrp receptors. To demonstrate the use of Nrp2 as a selective Sema3 inhibitor,
we assayed the ability of Nrp2 to selectively relieve Sema3-dependent inhibition
of VEGF-A binding. Selectivity would be demonstrated by a reduction of CfurSema mediated-inhibition and resultant gain in AP-VEGF-A binding to Nrp1
affinity plates. Nrp1 showed no ability to relieve the inhibition of Sema3F-mediated
inhibition. In fact, Nrp1 directly sequestered VEGF-A at high Nrp concentrations
resulting in complete loss of binding as expected (black line, Figure 7.5).
Remarkably, Nrp2 significantly enhanced the amount of VEGF-A retained on Nrp1
plates to 63% the level of retention seen in the absence of inhibition (grey line,
Figure 7.5). This provides direct evidence that Nrp2 is able to directly and
specifically sequester Sema3. Similarly, 37% recovery was seen with Nrp1 Chimera
(blue line, Figure 7.5), consistent with the reversal of specificity seen for VEGF-A
inhibition (Figure 7.3, B). These data demonstrates that the unique mechanisms
utilized by Nrp to preferentially bind different members of the Sema3 and VEGF
family ligands can be exploited to create Nrp inhibitors specific for different Nrp
ligand families.
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Figure 7.5: Nrp2 and Nrp1Chimera preferentially sequester Sema3F.
The ability of Nrp1, Nrp2, and Nrp1Chimera to selectively sequester C-furSema was
determined through combined incubation of Nrp, C-furSema3F, and AP-VEGF-A
in Nrp1 adsorbed affinity plates. Nrp1 was unable to relieve C-furSema-dependent
inhibition and completely abolished VEGF-A binding (black line). Conversely,
titration with Nrp2 promoted 63% recovery of VEGF-A binding demonstrating
selective sequestration of Sema3F (grey line). Nrp1Chimera also relieved CfurSema-dependent inhibition, promoting recovery of VEGF-A binding to 37% the
level of uninhibited VEGF-A (blue line). Experiments were performed in triplicate
and reported as the mean ± 1 S.D.
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Discussion
These data establish the basis for selective Nrp ligand binding to the b1
coagulation factor domain of Nrp. While both VEGF and Sema3 ligand families
share a partially overlapping ligand binding site in the Nrp b1 domain (Parker et
al., 2010), we demonstrate a series of residues that differ between Nrp1 and Nrp2
and contribute to the observed specific VEGF-A binding.
Nrp2Chimera possesses nearly full reversal of selectivity to the level of Nrp1,
indicating that the three altered regions represent the predominant regions
mediating specific VEGF-A binding. The TN/DGR L1-loop is highly divergent
between Nrp1 and Nrp2 and possesses the only insertion/deletion in the b1
domain. Mutation of this region results in the largest net loss of VEGF-A binding
to Nrp1, consistent with a direct interaction involving a hydrogen bond between
Nrp1-T299 and VEGF-A-E154 (Parker et al., 2012c). The KKK/QNG L3-loop
produces the largest net gain in Nrp2 binding to VEGF-A. Conserved residues in
the L3 loop form one wall of the C-terminal arginine binding pocket. The nonconserved KKK/QNG residues do not appear to directly engage VEGF-A in the
bound form. The residues are, however, very distinct in physical properties with
the Nrp1 loop being significantly more electropositive. VEGF-A contains a series
of conserved acidic residues in the C-terminus of its heparin-binding domain,
including E154 discussed above, which contribute to Nrp binding. This suggests
that the L3-loop may function by electrostatic steering of VEGF-A. This may
represent a general mechanism allowing specific binding of other Nrp1 specific
ligands such as VEGF-B and placental growth factor (PlGF) that also possess
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acidic residues in their heparin-binding domains. In contrast, Sema3 family
members and Nrp2-specific VEGF-C and VEGF-D do not possess these acidic
residues. A mutant Nrp2 containing R287E has previously been shown to possess
enhanced binding to VEGF-A (Geretti et al., 2007). We show that charge reversal
produces a decrease in Nrp1 binding to VEGF-A indicating a direct contribution to
ligand binding selectivity. Geretti and colleagues proposed that this may be due
to enhancing the electronegative potential of the b1 domain of Nrp2 favoring
binding to the electropositive VEGF-A. R287 is located in a helical region directly
adjacent to the L1 loop, suggesting that these regions interact to correctly position
these two structural elements, and thus the critical ligand binding coagulation
factor loops. While the NrpChimera molecules substantially reverse the observed
specificity for VEGF-A, the reversal does not reach the corresponding wild-type
level and one or more additional regions may also contribute to selective binding.

Copyright © Matthew W. Parker 2014
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CHAPTER 8: MICROPLATE-BASED SCREENING FOR SMALL MOLECULE
INHIBITORS OF NRP2/VEGF-C INTERACTIONS
Collectively, this dissertation has provided molecular details explaining the
mechanism of Nrp binding to multiple ligands, including Sema3, VEGF-A, and
VEGF-C. Using structural approaches we have demonstrated the physical basis
for Nrp1 and Nrp2 binding to the VEGF-A and VEGF-C family of ligands. Thus, we
are uniquely poised to develop inhibitors of Nrp ligand binding. Indeed, we have
already demonstrated the use of peptides (Chapters 3, 4, and 6) and soluble
receptor fragments (Chapters 6 and 7) for VEGF and Sema3 inhibition. However,
we are interested in expanding our investigation of Nrp inhibitory modalities
through the development of small molecule inhibitors that would be of significant
therapeutic interest.
Nrp2 inhibition is of particular interest due to its important role in
tumorigenesis. Nrp2 is highly expressed in lymphatic endothelial cells where it is
important for physiological lymphangiogenesis and can contribute to pathological
tumor lymphangiogenesis (Ellis, 2006; Parker et al., 2012a; Stacker et al., 2002).
Additionally, expression of Nrp2 and its ligand, VEGF-C, are induced in a variety
of cancer types and their expression is directly correlated with metastasis to
regional lymph nodes and advanced stage disease. Thus, blocking Nrp2 activation
by VEGF-C represents a promising anti-lymphangiogenesis therapeutic strategy.
Mature VEGF-C, produced through proteolytic removal of N- and C-terminal propeptides, binds domains b1b2 of Nrp2 (Karpanen et al., 2006). A number of Cterminal arginine containing molecules have been identified as inhibitors of
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Nrp/ligand binding (Parker et al., 2013). However, these compounds have limited
potency and thus identification of inhibitors that target secondary binding sites are
of significant interest (Guo et al., 2013). To identify novel small molecule inhibitors
of VEGF-C binding to Nrp2-b1b2, we developed and optimized an assay that
utilizes Nrp2-affinity plates and an alkaline phosphatase (AP) fusion of VEGF-C
(AP-VEGF-C) for detection of competitive inhibitors of ligand binding. We used this
assay to screen the National Institutes of Health (NIH) Clinical Collection, provided
through the NIH Molecular Libraries Roadmap Initiative, and we report the
identification of three inhibitors of VEGF-C binding to Nrp2.
To make Nrp2-b1b2-affinity plates, we expressed domains b1b2 of human
Nrp2 (Nrp2-b1b2, residues 276-595) in Escherichia coli (E. coli) strain Rosetta
Gami-2(DE3) (Novagen/EMD Millipore, Billerica, MA) as a hexa-histidine fusion
protein from pET28b (Novagen/EMD Millipore). Nrp2-b1b2 was purified in a twostep process via immobilized metal affinity chromatography (IMAC) (HIS-Select
HF Nickel Affinity Gel, Sigma-Aldrich, St. Louis, MO) followed by heparin affinity
chromatography (HiTrap Heparin HP, GE Healthcare Life Sciences, Pittsburgh,
PA) (Vander Kooi et al., 2007). Purified Nrp2-b1b2 was then diluted to 50 μg/mL
with 50 mM Na2CO3 pH 10.4 and immediately added to 96-well protein high-bind
microplates (Plate #9018, Corning, Corning, NY) and incubated for 1 h at 37°C.
Bovine serum albumin (BSA) (Simga-Aldrich) was used to coat control wells. The
plate was then aspirated, washed 5x 100 μL with PBS-T (phosphate buffered
saline, 0.1% Tween 20), and stored with 100 μL PBS-T at 4°C. To detect VEGF-C
binding to Nrp2-affinity plates, we produced mature mouse VEGF-C (residues 108-
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223) fused at its N-terminus to the reporter gene alkaline phosphatase (AP) (APVEGF-C). AP-VEGF-C was expressed via PEI mediated transient transfection of
Chinese hamster ovary suspension cells (CHO-S) (Aricescu et al., 2006; Longo et
al., 2013) from the pAPtag-5 vector (GenHunter Corporation, Nashville, TN). APVEGF-C conditioned media was then buffer exchanged into assay buffer (50 mM
NaCl, 200 mM Tris pH 7.4) and concentrated to an activity of 7 x 10 -1 u/mL. APVEGF-C binding to Nrp2-b1b2-affinity plates was detected by adding 100 μL of 1X
AP substrate and the evolution of para-nitrophenol phosphate was monitored by
measuring 405 nm absorption on a microplate reader. Prior to analysis the
absorbance of the control wells (BSA-coated) was used to background correct the
data.
The assay conditions for screening, including pH and buffer, salt, and
DMSO concentration, were optimized. First, we analyzed AP-VEGF-C binding to
Nrp2-b1b2-affinity plates over a pH range of 3 to 9 (Figure 8.1, A). 100 mM citrate
was used to buffer samples with a pH less than 6.5 and 100 mM Tris was used to
buffer samples with a pH greater than 6.5. The highest AP-VEGF-C binding was
observed as a stable plateau between pH = 5.5 and pH = 8. Reduction of pH below
5 eventually resulted in a complete loss of binding. The observed pH sensitivity of
AP-VEGF-C/Nrp2-b1b2 binding is consistent with the known requirement for a Cterminal arginine in Nrp ligands (Parker et al., 2012b; Vander Kooi et al., 2007). In
light of the observed sensitivity of AP-VEGF-C/Nrp2-b1b2 binding to extremes in
pH, we determined the effect of buffer concentration on binding (Figure 8.1, B).
AP-VEGF-C binding to Nrp2-b1b2-affinity plates was analyzed at physiological pH
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= 7.4 with Tris concentrations between 0 mM and 500 mM. The assay tolerated a
range of Tris concentrations, with the highest binding observed at 150 mM.
Additionally, we determined the effect of ionic strength on AP-VEGF-C/Nrp2-b1b2
binding (Figure 8.1, C). Binding was measured in 200 mM Tris pH 7.4 over a range
of NaCl concentrations, from 0 mM to 300 mM. The highest AP-VEGF-C binding
was observed at 50 mM NaCl and greater than 75% binding was observed for all
other NaCl concentrations tested. Collectively, we used these data to define the
assay buffer as 50 mM NaCl, 200 mM Tris pH 7.4 for producing the highest signalto-noise while maintaining tight control over pH.
As a final optimization step, we determined the effect of dimethylsulfoxide
(DMSO), a common solvent used in small molecule libraries, on AP-VEGF-C
binding to Nrp2-b1b2-affinity plates (Figure 8.1, D). AP-VEGF-C was prepared in
assay buffer and binding to Nrp2-b1b2 was analyzed in the presence of increasing
concentrations of DMSO, from 0% to 10% (v/v). DMSO markedly inhibited APVEGF-C/Nrp2-b1b2 binding with 60% of AP-VEGF-C binding lost at 2% DMSO.
Therefore, in order to maintain robust assay signal, a maximum of 2% DMSO was
not exceeded in subsequent experiments.
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Figure 8.1: Assay optimization.
(A) The pH sensitivity of AP-VEGF-C/Nrp2-b1b2 binding was analyzed over a pH
range of 3 to 9. (B) The effect of increasing Tris concentrations on AP-VEGFC/Nrp2-b1b2 was determined. (C) AP-VEGF-C/Nrp2-b1b2 binding was analyzed
for a range of NaCl concentrations. (D) DMSO tolerance was determined by
titrating DMSO with AP-VEGF-C and analyzing binding to Nrp2-b1b2-affinity
plates.
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With the optimized assay conditions, we then validated our approach by
testing the ability of the Nrp-binding inhibitory peptide, ATWLPPR (Parker et al.,
2010; Starzec et al., 2007; Starzec et al., 2006), which was initially identified as a
competitive inhibitor of Nrp1 ligand binding, to inhibit AP-VEGF-C binding to Nrp2b1b2 (Figure 8.2, A). Serial dilutions of ATWLPPR from 300 μM to 3 μM were
prepared in assay buffer containing AP-VEGF-C and 2% DMSO. ATWLPPR fully
inhibited AP-VEGF-C/Nrp2-b1b2 binding with an IC50 = 43 μM. This is consistent
with the previously published potency of this peptide against Nrp1 (IC50 = 60 μM)
and confirms that the core ligand binding pocket engaged by ATWLPPR is
conserved between Nrp1 and Nrp2 (Starzec et al., 2006). These data confirm the
functionality of our assay in characterizing inhibitors of VEGF-C/Nrp2-b1b2
binding.
C-terminal arginine-like compounds have established efficacy for inhibition
of VEGF/Nrp binding (Jarvis et al., 2010). However, these compounds suffer from
limited potency and thus we aimed to identify non-C-terminal arginine-like
inhibitors. The NIH Clinical Collection is a diverse small molecule library of
approximately 450 drug-like compounds that have a history of clinical testing with
known safety profiles. We screened the NIH Clinical Collection for inhibitors of
VEGF-C/Nrp2-b1b2 binding (Figure 8.2, B, PubChem BioAssay AID: 16941),
testing each compound at 200 μM (2% DMSO). The quality of the results were
evaluated by two commonly used parameters in high-throughput screens: signalto-noise (S/N) and Z-factor (Z), the latter takes into account both the assay
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dynamic range and signal variability. By these two parameters our assay was
defined as high quality with an average across-plate S/N = 32 and Z = 0.55 (Zhang
et al., 1999). The data were Z-score normalized (rescaled to set the mean signal
(Σ) = 0 with a standard deviation (σ) = 1) (Malo et al., 2006), thus allowing direct
comparison of each compound’s activity across different plates. The Z-score for
each compound was plotted and a stringent “hit” criteria was defined as differing
by more than 3.5 standard deviations from the mean. This selection criteria
restricted hits to <1% of the screened compounds and included only inhibitors
(Figure 8.2, B, dashed line). Importantly, all hit compounds were tested for the
ability to directly alter the activity of AP, resulting in a false positive, and no effect
was observed.
Three compounds exceeded the criteria for a hit: Zafirlukast (σ = -5.3),
dihydrexidine HCl (σ = -4.3), and Actinomycin D (σ = -4.0). Each hit was confirmed
by preparing a concentrated compound stock (50 mM) in 100% DMSO and
measuring the inhibitory potency against AP-VEGF-C/Nrp2-b1b2 binding in
triplicate (Figure 8.2, C). All hit compounds showed greater than 90% inhibition of
AP-VEGF-C/Nrp2-b1b2 binding and their relative potencies were consistent with
the initial screen. Zafirlukast (Santa Cruz Biotechnology, Dallas, TX) was the most
potent inhibitor with an IC50 = 66 μM, dihydrexidine hydrochloride (Tocris
Bioscience, Bristol, UK) was the weakest inhibitor (IC50 = 113 μM), and
Actinomycin D (Tocris Bioscience) fell in between these two compounds (IC50 = 92
μM). Zileuton (Santa Cruz Biotechnology), a drug structurally distinct from
Zafirlukast but also a leukotriene receptor antagonist, was tested alongside the
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compounds and showed no ability to inhibit AP-VEGF-C/Nrp2-b1b2, indicating the
specific activity of these compounds.
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Figure 8.2: Screen for small molecule inhibitors.
(A) The ability of the peptide ATWLPPR to inhibit AP-VEGF-C/Nrp2-b1b2 binding
was determined. ATWLPPR inhibited binding with an IC50 = 43 μM. (B) The NIH
Clinical Collection small molecule library was screened for inhibitors of AP-VEGFC/Nrp2-b1b2 binding. Three compounds exceeded the hit criteria (dashed line),
reducing binding by more than 3.5 standard deviations from the mean. (C) Hits
were validated by titrating each compound with AP-VEGF-C and measuring Nrp2b1b2 binding. Zafirlukast, Actinomycin D, and Dihydrexidine inhibited AP-VEGFC/Nrp2-b1b2 binding with IC50 = 66, 92, and 113 μM, respectively. Zileuton was
unable to inhibit binding. (D) Chemical structure of the identified hit compounds.
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CHAPTER 9: DISCUSSION
Future Directions of Nrp Research
Cumulatively, the work described in this dissertation defines the molecular
basis for binding of the Sema3 and VEGF family of ligands to the Nrp family of
essential cell surface receptors. Importantly, we have demonstrated that both Nrp1
and Nrp2 contain a C-terminal arginine binding pocket used for the high-affinity
binding of both ligand families along with accessory sites to tune potency and
specificity. The utilization of a common binding site by both VEGF and Sema3
underlies their observed competitive binding and provides an explanation for their
functional competition observed in vivo.
Because of the complex interplay of Nrp with other molecules, a number of
critical areas regarding the mechanism of Nrp function remain to be explored. Of
particular interest is the specific role for Nrp in distinct signaling cascades and
tissue types. Connected to this is the extent to which Nrp functions by the same
general mechanism in highly diverse pathways or if there are distinct mechanisms
employed in different signaling cascades.
Nrp Function as an Essential Co-receptor
The nature of Nrp coupling to signaling receptors to form a functional
signaling holocomplex is a major area of future research. In particular, unique
heterophilic receptor/receptor contacts are likely critical to the formation and
stability of the complex. Although necessary for signaling, the role of the Nrp MAM
domain is largely unknown. Thus, the MAM domain might physically couple to
cognate receptors. Indeed, the membrane proximal seventh Ig-like domain of
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VEGFR-2 has been shown to form a dimer required for activation (Ruch et al.,
2007; Yang et al., 2010), which could be coupled to MAM domain function in the
holo-complex. Further, the specific function of the transmembrane domain of Nrp
may be to directly couple to signaling receptors or to allow precise physical
arrangement of the intracellular domain. The transmembrane domain of VEGFR2 has been demonstrated to facilitate correct orientation of homo-dimers to couple
ligand binding to receptor activation (Dosch and Ballmer-Hofer). Nrp may require
similar specific alignment of the transmembrane domain and may, in fact, directly
couple to the transmembrane domain of cognate signaling receptors. Indeed, it is
possible that the extracellular juxtamembrane, transmembrane, and intracellular
juxtamembrane domains may coordinately function to physically couple ligand
binding to receptor activation.
The function of the intracellular domain of Nrp and the extent to which Nrp
can function independently of a canonical signaling receptor, for example VEGFR
or Plexin, remains to be determined. Of particular interest are the molecules that
can form direct interactions or indirectly bridge with Nrp. While GIPC is clearly a
critical Nrp adaptor protein, other PDZ-domain proteins have also been suggested
to function with Nrp. In particular, Nrp was recently identified as a positive regulator
of hedgehog signaling (Hillman et al., 2011) and the PDZ-domain protein required
for this activity is currently being pursued. Connected to this is the extent to which
autocrine signaling represents a fundamental mode of Nrp activation in disease,
with particular interest in the connection to cancer stem cell maintenance.
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Physical basis for Sema3 function via Nrp receptors
We have investigated the molecular basis for Sema3 binding to the Nrp
family of receptors. In Chapter 3 we demonstrated that the Sema3 family is
processed at a conserved furin recognition site in the C-terminal domain. This
processing directly regulates Nrp binding and VEGF competition. Additionally,
Chapter 4 describes specific differences in the furin recognition site across the
Sema3 family and how the strength of the consensus site and Nrp binding is
inversely correlated. While it is clear that only the processed form of Sema3 is able
to function as a VEGF pathway inhibitor, the role of C-terminal processing of
Sema3 in axon guidance is an intriguing area that remains to be explored. The Cterminal domain of Sema3 is necessary, but not sufficient, for its function in axon
guidance. Sema3 additionally requires an interaction between its sema domain
and the a1 domain of Nrp (Gu et al., 2002; Klostermann et al., 1998; Mamluk et
al., 2002). It is interesting to note that the C-terminal Fc fusion of Sema3, which
represents the unprocessed form of Sema3, is able to cause axon repulsion in situ
(Appleton et al., 2007; Cheng et al., 2004).

Thus, both processed and

unprocessed forms of Sema3 are able to function in situ in axon guidance. In vivo,
furin processing may be solely utilized as a mechanism regulating the antiangiogenic activity of Sema3 or it may alter the potency and range of activity of
Sema3 in axon guidance. Alternatively, VEGF has well characterized neurotrophic
and neuroprotective effects and it is possible that furin processing of Sema3 could
affect the ability of VEGF to compete for Nrp binding on the surface of neuronal
and glial cells.
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While the basis for ligand binding specificity has come into focus through
our work, the contribution of physical mechanisms governing ligand binding
selectivity versus tissue specific expression remains to be determined.

The

physical basis for divalent Sema3 binding to Nrp remains an important unanswered
question.

Specifically, the contribution and coupling between the a1 and b1

interaction sites and the effect of post-translational modification by furin to binding
and signaling remain outstanding questions.
Intriguingly, these data also have direct implications for the in vivo function
of differential furin processing in Kallmann’s syndrome, a genetic disease
characterized by incomplete development of olfactory nerve fibers and defective
migration of neuroendocrine cells. A recent analysis of patients revealed mutations
in the Sema3A gene underlying the disease, including R733H (Hanchate et al.,
2012). R733 is the C-1 residue of the Sema3A.1 furin site (Adams et al., 1997).
Although R733H was efficiently expressed and secreted, it exhibited a marked and
significant reduction in its ability to signal (Hanchate et al., 2012). The results
presented within this dissertation suggest that this mutation would reduce furin
processing at the Sema3A.1 site, one of three furin consensus sites within the
basic domain. Thus, differential processing and Nrp engagement of the different
furin sites has important function in both normal physiology and pathology. Our
data provide a mechanistic basis for understanding the effect of mutations on both
furin processing and Nrp binding.
Semaphorin-like proteins are produced by a variety of viruses that utilize
molecular mimicry. Various poxviruses encode SemaV family members, which
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are sema domain proteins homologous to the N-terminus of semaphorin (Yazdani
and Terman, 2006). SemaV family members have been shown to induce changes
in host cytoskeletal dynamics, thereby altering the adherence and spreading of
infected cells (Walzer et al., 2005). It has recently been shown that Nrp is essential
for HTLV-1 viral entry (Ghez et al., 2006). The HTLV-1 coat protein is a heparin
binding protein that directly interacts with Nrp (Lambert et al., 2009). Further, the
interaction and infectivity of HTLV-1 can be attenuated by both VEGF-A and
peptide inhibitors of Nrp (Lambert et al., 2009). Intriguingly, the HTLV coat protein
that interacts with Nrp requires furin processing for maturation and infectivity
(Hasegawa et al., 2002). From our studies, we suggest that HTLV-1 utilizes
molecular mimicry of the mature furin processed form of Sema3 to target the
shared Sema3/VEGF binding site in the b1 domain of Nrp. This insight provides
a novel avenue for potential therapeutic intervention in HTLV-1 infected
individuals.
Nrp Inhibition in Spinal Cord Injury
Nrp function in Sema3 signaling is important not only for physiological axon
guidance, but also for signaling in spinal cord injury (Pasterkamp and Giger, 2009;
Zhou et al., 2008). Following spinal cord injury, a glial scar forms to stabilize and
seal the wound. However, the glial scar also serves as a barrier to regenerating
axons due to production of axon repulsion molecules.

Sema3 expression

significantly contributes to the inhibitory nature of the glial scar and so inhibitors of
Nrp-Sema3 signaling hold promise as therapeutics for treatment of spinal cord
injury (De Winter et al., 2002; Fawcett, 2006; Pasterkamp et al., 1999).
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The use of soluble Nrp as a modulator of VEGF-mediated angiogenesis has
been the target of numerous studies. However, soluble Nrp as a modality for
blocking the chemorepulsive function of Sema3 is less established even though
clear clinical applications exist for neutralizing molecules in spinal cord injury
(Niclou et al., 2006). The efficacy of targeting this signaling axis is demonstrated
by a small molecule inhibitor of the Sema3A/Nrp1 interaction (Kikuchi et al., 2003)
that, when given to rats following spinal cord transection, shows enhanced
regeneration of axons across the glial scar (Kaneko et al., 2006). Additionally,
initial work has demonstrated that Nrp2 inhibition allows penetration of axons into
a model glial scar (Shearer et al., 2003). Two outstanding issues remain to be
solved. First, many members of the Sema3 family can mediate this deleterious
axonal repulsion, so a potent pan-Sema3 inhibitory modality is desired (De Winter
et al., 2002). Second, selective inhibition of Sema3 signaling without effecting
VEGF-A signaling is desired to maximally promote recovery following injury. Nrp2
molecules engineered for increased potency, by oligomerization with an Fc or
related strategy, have the potential to be used as selective Sema3-traps. One
promising approach is to repurpose s9Nrp2B for use against Sema3.
Through understanding the molecular basis for Nrp’s specific binding of its
ligands, engineered soluble Nrp receptors can be designed with specificity for a
particular ligand. The binding of Sema3F shows little selectivity between Nrp1 and
Nrp2. Further, the observed inhibitory potency of Nrp1 for VEGF-A and Sema3F
is virtually identical in absolute terms. Thus, Nrp1 was found to be equally capable
of sequestering both VEGF-A and Sema3F and suggests that Nrp1 has utility as
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a broad-spectrum Nrp ligand inhibitor. In contrast, Nrp2 is found to selectively
sequester Sema3F. The reported chimeric Nrps have utility for discriminating
between the contribution of VEGF-A and Sema3F function in a particular system.
Previous work has reported Nrp1 mutations in the a1 domain that allow production
of a VEGF-A selective Nrp1 (Gu et al., 2002). The Nrp1Chimera reported here
represents a complimentary molecule that is selective for Sema3F, with utility in
differentiating between specific effects mediated by the different Nrp1 ligands.
Additionally, molecules specific for certain members of the Sema3 family could
potentially be produced by combinatorial approaches using the a1 domain of
Nrp1/Nrp2 for specificity in combination with the b1 domain of Nrp2. Our studies
demonstrate the mechanism underlying Nrp coagulation factor domain-mediated
ligand binding selectivity and advances the search for potent and selective
inhibitors of Nrp signaling.
Physical basis for VEGF function via Nrp receptors
We have determined the structure of VEGF-A and VEGF-C in complex with
their cognate Nrp receptor, Nrp1 and Nrp2, respectively. The loss of Nrp binding
by VEGF-C and VEGF-A C-terminal arginine mutants, or to Nrp mutants with an
occluded binding pocket, demonstrates the use of a C-terminal arginine for ligand
engagement. Indeed, both the VEGF-A and VEGF-C free carboxylate forms
extensive interactions with the Nrp-b1 binding pocket. Interestingly, the C-terminal
domain is the most variable region within the VEGF family and VEGF-C is not the
only VEGF family member that, in the absence of post-translational modification,
lacks a C-terminal arginine. Of the five VEGF family members, three family

157

members contain Nrp-binding isoforms that lack this structural motif (VEGF-C,
VEGF-D, and VEGF-B186). VEGF-D, a close structural and functional homologue
of VEGF-C, is processed at an equivalent site in its C-terminus to produce a Cterminal arginine (Stacker et al., 1999) and thus likely utilizes a similar binding
mode to Nrp2. This observation provides additional functional insight, as loss of
VEGF-D C-terminal processing also ablates function in vivo (Harris et al., 2013).
The collective results from studies of both VEGF-C (Chapter 5) and VEGFA (Chapter 6) raise important questions regarding the function and receptor
binding properties of the VEGF-B family of pro-angiogenic cytokines. Interestingly,
there are three VEGF-B isoforms, VEGF-B167, VEGF-B127, and VEGF-B186, all of
which differ in their C-terminal domain (Olofsson et al., 1996a; Olofsson et al.,
1996b). Characterization of VEGF-B186 demonstrated that it exhibited proteolyticdependent binding to Nrp1 and identified the site of proteolysis as R227 (Makinen
et al., 1999). These data suggest that VEGF-B186 may exhibit a similar mechanism
of activation as that observed for VEGF-C. Alternatively, VEGF-B167 contains a
heparin-binding domain similar to VEGF-A165 and VEGF-B127 appears homologous
to VEGF-A121. Thus, the VEGF-B family contains multiple members that share
similarities with divergent members of the VEGF family and, as such, represents
an important area for future research.
Our data also suggest a physical basis for the observed functional
differences of VEGF family members and isoforms within specific VEGF families.
We have demonstrated that VEGF-A164 selectively physically engages Nrp1 and
exhibits dramatically reduced binding to Nrp2, thus explaining the functional
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specificity of VEGF-A164 in angiogenesis. Further, VEGF-A164 is well documented
as the most potent VEGF-A isoform in stimulating angiogenesis.

It is well

recognized that VEGFR dimerization, while necessary, is insufficient for activation.
Indeed, a specific dimeric organization of the juxtamembrane domain of VEGFR2 has been shown to be critical to couple ligand binding to intracellular receptor
activation (Dosch and Ballmer-Hofer; Yang et al., 2010). It is possible that the
observed binding imposes specific steric constraints, allowing a stable
organization of the heterohexameric VEGF-A/Nrp1/VEGFR-2 signaling complex.
Indeed, the heparin binding residues of the HBD (Krilleke et al., 2007) and Nrp1b1 domain (Vander Kooi et al., 2007) are positioned spatially close together in the
complex.

This

spatial

orientation

would

allow

binding

of

a

single

glycosaminoglycan (GAG)/heparin chain by the protein complex and further
reinforce the specific orientation of the signaling complex. Our data establishes
the unique physical engagement of VEGF-A164 by Nrp1 and opens up new
avenues to explore the specific physical mechanism of Nrp in angiogenesis.
Nrp Inhibition in Tumor Angiogenesis
Inhibitory

modalities

targeting

Nrp1-dependent

angiogenesis have been extensively explored.

VEGF-A

induced

A soluble Nrp splice form,

containing only the ligand binding region of the extracellular domain of Nrp has
been employed and found to inhibit tumorigenesis (Gagnon et al., 2000).

A

number of peptides and a synthetic peptidomimetic inhibitor of Nrp have been
described (Jarvis et al., 2010; Parker et al., 2010; Starzec et al., 2006; von Wronski
et al., 2006). Methods to overexpress inhibitory molecules, for example Sema3A,
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have been reported with promising activity in tumor angiogenesis (Casazza et al.,
2011). Finally, antibodies targeting both Nrp1 and Nrp2 have been developed that
show promising activity in animal models with observed devascularization of solid
tumors and decreases in metastasis (Caunt et al., 2008; Liang et al., 2007). These
anti-Nrp antibodies are currently being tested in clinical trials. Surprisingly, one of
the observed side effects of administration of the Nrp1 antibody, MNRP1685A,
was platelet depletion (Weekes et al., 2014). This was shown to be due to platelet
activation, aggregation, and clearance.
While significant effort has been devoted to blocking aberrant VEGF-A
signaling, only recently has VEGF-C been identified as a promising target for
cancer therapeutics. Aberrant activation of VEGF-C signaling via Nrp2 is
associated with cancer initiation, survival, and progression (Ellis, 2006; Stacker et
al., 2002). The Nrp2/VEGF-C signaling axis contributes to tumorigenesis via
multiple mechanisms. Mimicking its physiological function, VEGF-C signaling via
Nrp2 stimulates lymphatic vessel recruitment to tumors and directly contributes to
cancer metastasis (Caunt et al., 2008). Importantly, the role of VEGF-C and Nrp2
in tumorigenesis is not exclusively associated with aberrant lymphangiogenesis.
Indeed, in situ studies have demonstrated that autocrine VEGF-C signaling in
breast cancer cells stimulates cellular motility (Timoshenko et al., 2007). Further,
recent reports indicate that cancer cell survival is enhanced through VEGFC/Nrp2-dependent autophagy (Stanton et al., 2012) and that autocrine Nrp2
signaling maintains the population of cancer stem cells (Goel et al., 2013). VEGFC also functions to protect prostate cancer cells from oxidative stress in a Nrp2-
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dependent fashion (Muders et al., 2009). Thus, selective inhibition of Nrp2
represents a promising, multipronged anti-cancer therapeutic strategy.
Secreted splice forms of angiogenic receptors have essential roles in vivo
(Albuquerque et al., 2009; Ambati et al., 2006; Kendall and Thomas, 1993) and
have been engineered to serve as therapeutic inhibitors that block aberrant
pathway activation by ligand sequestration (Stewart, 2012). In Chapter 5 we
demonstrate that the alternative Nrp2 splice form, s9Nrp2B, potently sequesters
VEGF-C and inhibits binding to Nrp2. The biological function and localized tissuespecific expression of s9Nrp2 is of significant interest. Indeed, s9Nrp2 may be
analogous or complement the secreted splice form of VEGFR-2, sVEGFR-2, which
functions as an endogenous lymphangiogenesis inhibitor in the eye (Albuquerque
et al., 2009). VEGF-D also functions in lymphatic angiogenesis and has been
shown to have partially overlapping biological function with VEGF-C and important
pathological functions (Haiko et al., 2008; Harris et al., 2013; Karpanen et al.,
2006). The conservation of Nrp2-interacting residues between VEGF-C and
VEGF-D strongly suggest that s9Nrp2B will equivalently sequester both VEGF-C
and VEGF-D. In contrast, Nrp2 is physically and functionally separate from VEGFA (Parker et al., 2012b; Parker et al., 2012c). Thus, s9Nrp2B is likely to selectively
sequester the lymphangiogenic-specific VEGF family members, VEGF-C and
VEGF-D.
Development of Nrp Inhibitors
This dissertation has demonstrated parallel strategies for inhibiting Nrp ligand
binding, including peptide inhibitors, soluble receptor fragments, and small
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molecules. These unique inhibitory modalities provide an important basis for future
studies aimed at optimizing the selectivity and potency of Nrp inhibitors for use
therapeutically in cancer and spinal cord injury.
Two major classes of peptide-based Nrp inhibitors have been described
(Starzec et al., 2006; von Wronski et al., 2006).

Both are relatively small

monomeric peptides (5-7 residues) with modest inhibitory potency (mid-mM). It
has been unclear if this modest potency is due to specific features of the peptides
or if it represents a general problem with this mode of inhibiting angiogenesis. Our
results from Chapter 2 reveal that C-furSema is able to inhibit binding of VEGF-A
to Nrp with an increase in potency of two to three orders of magnitude relative to
previous inhibitors. It will be interesting to determine the physical basis for this
enhanced potency. It is notable that while dimeric VEGF was found to directly
antagonize Sema3 mediated growth cone collapse, a monomeric peptide inhibitor
derived from the C-terminus of VEGF reversed this effect (Cheng et al., 2004). CfurSema contains the strictly conserved intermolecular disulfide, and the
multimeric state of the peptide may well contribute to its enhanced potency.
Additionally, the C-terminal region of all known anti-angiogenic Sema3s shows
conservation beyond the terminal 5-7 residues. This suggests that additional
binding pockets on Nrp may be employed which are not exploited by current
generation peptides. Together, these results strongly suggest that potent peptide
inhibitors of Nrp can be produced, opening exciting avenues to design novel
inhibitors based on Sema3F and other endogenous angiogenesis inhibitors.
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A second inhibitory modality is soluble receptor fragments that function by
sequestering ligand from the active signaling complex. In Chapters 7 we describe
a monomeric fragment of Nrp capable of sequestering VEGF and Sema3 with
modest potency. The practice of engineering inhibitor multimerization to increase
potency is well established for soluble receptor fragments. Most commonly, soluble
receptors are dimerized by expression as an Fc fusion protein (e.g. VEGF-trap,
discussed earlier, Fc-sVEGFR3 (Lin et al., 2005), and Fc-sVEGFR1/2 (Holash et
al., 2002)). The dimeric soluble fragment of Nrp2 presented in Chapter 7, s9Nrp2B,
represents a unique mechanism for generation of a multimeric protein that
maintains the benefits of avidity but does not require introduction of an exogenous
polypeptide sequence. s9Nrp2B showed significant gains in potency relative to the
monomeric inhibitor against VEGF-C and remains to be tested against the Sema3
family. Importantly, this is likely to function as a selective VEGF-C inhibition as
VEG-A is physically and functionally separate from Nrp2. Additional optimization
of s9Nrp2B potency, selectivity, and stability is an important future direction for the
development of a therapeutically useful inhibitor.
In parallel with the strategies described above, we report in Chapter 8 the
development of a VEGF-C/Nrp2 binding assay that we used to screen a small
molecule compound library for inhibitors of Nrp2. We identified three novel
inhibitors of VEGF-C/Nrp2 binding.

Intriguingly, both Actinomycin D and

Zafirlukast are used to treat disease states, tumor angiogenesis and asthma,
respectively, where anti-angiogenesis has been suggested to be an important
beneficial secondary effect of treatment (Lee et al., 2011) (Blumberg, 1974). In
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both cases, a direct contribution of Nrp inhibition in the biological activities of these
compounds is an important area for future studies. Additionally, the development
of this assay opens the door for screening other large chemically diverse small
molecule libraries to identify more potent inhibitors of VEGF-C function. Notably,
none of the three molecules identified contain a C-terminal arginine-like moiety,
thus providing novel lead compounds for optimization and combinatorial
approaches towards the production of a potent and selective small molecules Nrp2
inhibitor. Continued development of novel inhibitory modalities targeting the
different fundamental mechanisms of Nrp action will be both mechanistically
informative and have direct relevance to human health.
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